

CITATION REPORT

List of articles citing

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpo

DOI: 10.1038/ncomms10501
Nature Communications, 2016, 7, 10501.

Source: <https://exaly.com/paper-pdf/65511377/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1033	Galectin-9 increases Tim-3+ dendritic cells and CD8+ T cells and enhances antitumor immunity via galectin-9-Tim-3 interactions. 2008 , 181, 7660-9		147
1032	The head and neck cancer immune landscape and its immunotherapeutic implications. 2016 , 1, e89829		356
1031	Is There Still Room for Cancer Vaccines at the Era of Checkpoint Inhibitors. 2016 , 4,		44
1030	Differential Expression of Immune Checkpoint Modulators on In Vitro Primed CD4(+) and CD8(+) T Cells. 2016 , 7, 221		14
1029	Recent Advances in Immunotherapy in Metastatic NSCLC. 2016 , 6, 239		23
1028	Immune checkpoint inhibitors: the new frontier in non-small-cell lung cancer treatment. 2016 , 9, 5101-16		26
1027	Molecular and clinical characterization of PD-L1 expression at transcriptional level via 976 samples of brain glioma. 2016 , 5, e1196310		116
1026	Emerging therapeutic agents for lung cancer. 2016 , 9, 138		65
1025	Immune checkpoint proteins PD-1 and TIM-3 are both highly expressed in liver tissues and correlate with their gene polymorphisms in patients with HBV-related hepatocellular carcinoma. 2016 , 95, e5749		53
1024	Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure). 2016 , 27, 1492-504		280
1023	Learning from PD-1 Resistance: New Combination Strategies. 2016 , 22, 448-451		52
1022	Synthetic lethality in lung cancer and translation to clinical therapies. 2016 , 15, 61		23
1021	Catching up with solid tumor oncology: what is the evidence for a prognostic role of programmed cell death-ligand 1/programmed cell death-1 expression in B-cell lymphomas?. 2016 , 101, 1144-1158		6
1020	Genomic Approaches to Understanding Response and Resistance to Immunotherapy. 2016 , 22, 5642-5650		98
1019	Impaired functional responses in follicular lymphoma CD8TIM-3 T lymphocytes following TCR engagement. 2016 , 5, e1224044		23
1018	Unmasking PD-1 Resistance by Next-Generation Sequencing. 2016 , 375, 888-9		6
1017	Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors. 2016 , 113, E7769-E7777		116

1016	Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?. 2016 , 8, 111	40
1015	Increased TIM3+CD8+T cells in Myelodysplastic Syndrome patients displayed less perforin and granzyme B secretion and higher CD95 expression. 2016 , 51, 49-55	10
1014	A Portal Vein Injection Model to Study Liver Metastasis of Breast Cancer. 2016 ,	26
1013	Multiple Inhibitory Pathways Contribute to Lung CD8+ T Cell Impairment and Protect against Immunopathology during Acute Viral Respiratory Infection. 2016 , 197, 233-43	16
1012	Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. 2016 , 6, 827-37	561
1011	Immunotherapy: PD-1 says goodbye, TIM-3 says hello. 2016 , 13, 202-3	38
1010	T-cell immunoglobulin mucin 3 blockade drives an antitumor immune response in head and neck cancer. 2017 , 11, 235-247	50
1009	Immune Checkpoint Inhibitors in Lung Cancer - An Unheralded Opportunity?. 2017 , 29, 207-217	5
1008	IFN Signaling and ICB Resistance: Time is on Tumor's Side. 2017 , 3, 161-163	6
1007	Defining an inflamed tumor immunophenotype in recurrent, metastatic squamous cell carcinoma of the head and neck. 2017 , 67, 61-69	35
1006	Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma. 2017 , 75, 47-55	99
1005	Immune biomarkers for prognosis and prediction of responses to immune checkpoint blockade in cutaneous melanoma. 2017 , 6, e1299303	14
1004	Reactivation of dormant anti-tumor immunity - a clinical perspective of therapeutic immune checkpoint modulation. 2017 , 15, 5	23
1003	Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. 2017 , 168, 707-723	2141
1002	Immune checkpoint receptors in cancer: redundant by design?. 2017 , 45, 37-42	16
1001	Preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma. 2017 , 6, e1295903	42
1000	Tim-3 and its role in regulating anti-tumor immunity. 2017 , 276, 97-111	367
999	The Role of Immune Checkpoint Inhibition in the Treatment of Brain Tumors. 2017 , 14, 1049-1065	15

998	Co-inhibitory blockade while preserving tolerance: checkpoint inhibitors for glioblastoma. 2017 , 276, 9-25	11
997	Avelumab: combining immune checkpoint inhibition and antibody-dependent cytotoxicity. 2017 , 17, 515-523	36
996	JAK-STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation to decrease anti-PD-1 immunotherapy efficacy in pancreatic cancer. 2017 , 6, e1291106	83
995	Clinical Features of Acquired Resistance to Anti-PD-1 Therapy in Advanced Melanoma. 2017 , 5, 357-362	24
994	Resistance to immunotherapy: clouds in a bright sky. 2017 , 35, 649-654	8
993	Epigenetics and immunotherapy: The current state of play. 2017 , 87, 227-239	128
992	Interleukin-17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade. 2017 , 12, 1268-1279	99
991	Immunotherapeutic strategies in non-small-cell lung cancer: the present and the future. 2017 , 9, 507-520	8
990	Blockade of IDO-kynurenine-AhR metabolic circuitry abrogates IFN- γ -induced immunologic dormancy of tumor-repopulating cells. <i>Nature Communications</i> , 2017 , 8, 15207	17.4 90
989	Transient immunological and clinical effectiveness of treating mice bearing premalignant oral lesions with PD-1 antibodies. 2017 , 140, 1609-1619	11
988	The Era of Checkpoint Blockade in Lung Cancer: Taking the Brakes Off the Immune System. 2017 , 14, 1248-1260	10
987	Hallmarks of response to immune checkpoint blockade. 2017 , 117, 1-7	138
986	Novel Checkpoints and Cosignaling Molecules in Cancer Immunotherapy. 2017 , 23, 23-31	12
985	DNA Damage and Repair Biomarkers of Immunotherapy Response. 2017 , 7, 675-693	331
984	Dacarbazine-Loaded Hollow Mesoporous Silica Nanoparticles Grafted with Folic Acid for Enhancing Antimetastatic Melanoma Response. 2017 , 9, 21673-21687	37
983	Integrating Next-Generation Dendritic Cell Vaccines into the Current Cancer Immunotherapy Landscape. 2017 , 38, 577-593	190
982	Gastric adenocarcinoma. 2017 , 3, 17036	251
981	Immunotherapy resistance: the answers lie ahead - not in front - of us. 2017 , 5, 10	12

980	Primary and acquired resistance to PD-1/PD-L1 blockade in cancer treatment. 2017 , 46, 210-219	71
979	Development of CAR T cells designed to improve antitumor efficacy and safety. 2017 , 178, 83-91	67
978	Immunotherapy in malignant melanoma: recent approaches and new perspectives. 2017 , 4, 39-48	6
977	Molecular genetic and immunotherapeutic targets in metastatic melanoma. 2017 , 471, 281-293	14
976	Current FDA-approved treatments for non-small cell lung cancer and potential biomarkers for its detection. 2017 , 90, 24-37	27
975	Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer. 2017 , 6, e1261779	152
974	Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. 2017 , 7, 264-276	491
973	Potential Predictive Value of and Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma. 2017 , 23, 3012-3024	442
972	Combined immunotherapy with anti-PDL-1/PD-1 and anti-CD4 antibodies cures syngeneic disseminated neuroblastoma. 2017 , 7, 14049	27
971	Natural killer cell immunotherapies against cancer: checkpoint inhibitors and more. 2017 , 31, 55-63	73
970	Cancer Evolution during Immunotherapy. 2017 , 171, 740-742	18
969	Cancer Immunotherapy Getting Brainy: Visualizing the Distinctive CNS Metastatic Niche to Illuminate Therapeutic Resistance. 2017 , 33-35, 23-35	15
968	PD-L1 IHC in NSCLC with a global and methodological perspective. 2017 , 113, 102-105	25
967	Tim-3 signaling in peripheral NK cells promotes maternal-fetal immune tolerance and alleviates pregnancy loss. 2017 , 10,	54
966	Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer. 2017 , 7, 1420-1435	302
965	The role of T-cell immunoglobulin mucin-3 and its ligand galectin-9 in antitumor immunity and cancer immunotherapy. 2017 , 60, 1058-1064	12
964	Putative predictors of efficacy for immune checkpoint inhibitors in non-small-cell lung cancer: facing the complexity of the immune system. 2017 , 17, 1055-1069	19
963	Antibody-Based Therapeutics in Oncology. 2017 , 521-585	

962	Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40. 2017 , 23, 6165-6177	179
961	Check point inhibitors as therapies for infectious diseases. 2017 , 48, 61-67	27
960	T Cells Deficient in Diacylglycerol Kinase β Are Resistant to PD-1 Inhibition and Help Create Persistent Host Immunity to Leukemia. 2017 , 77, 5676-5686	13
959	Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors. 2017 , 23, 6982-6992	169
958	Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy. 2017 , 31, 64-75	74
957	From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials Wisely. 2017 , 23, 4980-4991 ₁₂	
956	A Natural CCR2 Antagonist Relieves Tumor-associated Macrophage-mediated Immunosuppression to Produce a Therapeutic Effect for Liver Cancer. 2017 , 22, 58-67	67
955	Tumor Evolution as a Therapeutic Target. 2017 ,	108
954	The immune contexture in cancer prognosis and treatment. 2017 , 14, 717-734	935
953	Novel Microwave Torso Scanner for Thoracic Fluid Accumulation Diagnosis and Monitoring. 2017 , 7, 304	13
952	Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2. 2017 , 25, 1163-1174 ₁₅₃	
951	Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer. 2017 , 2, e000213	152
950	Immunomodulatory effects of current cancer treatment and the consequences for follow-up immunotherapeutics. 2017 , 13, 1649-1663	6
949	A Co-Inhibitory Alliance in Myeloid Leukemia: TIM-3/Galectin-9 Complex as a New Target for Checkpoint Blockade Therapy. 2017 , 23, 6-7	10
948	[Clinical pharmacology and immunotherapy, 4th edition of the congress of pharmacology of anticancer drugs]. 2017 , 104, 807-811	0
947	Dacarbazine nanoparticle topical delivery system for the treatment of melanoma. 2017 , 7, 16517	31
946	De-novo and acquired resistance to immune checkpoint targeting. 2017 , 18, e731-e741	383
945	Tumor microenvironment changes leading to resistance of immune checkpoint inhibitors in metastatic melanoma and strategies to overcome resistance. 2017 , 123, 95-102	34

944	New B7 Family Checkpoints in Human Cancers. 2017 , 16, 1203-1211	126
943	Constitutive and acquired mechanisms of resistance to immune checkpoint blockade in human cancer. 2017 , 36, 17-24	18
942	Blimp-1 impairs T cell function via upregulation of TIGIT and PD-1 in patients with acute myeloid leukemia. 2017 , 10, 124	30
941	Predictive biomarkers for the efficacy of peptide vaccine treatment: based on the results of a phase II study on advanced pancreatic cancer. 2017 , 36, 36	18
940	Strategies for monitoring and combating resistance to combination kinase inhibitors for cancer therapy. 2017 , 9, 37	39
939	Differential intratumoral distributions of CD8 and CD163 immune cells as prognostic biomarkers in breast cancer. 2017 , 5, 39	40
938	The future of immune checkpoint cancer therapy after PD-1 and CTLA-4. 2017 , 9, 681-692	69
937	Rationally combining immunotherapies to improve efficacy of immune checkpoint blockade in solid tumors. 2017 , 36, 5-15	33
936	Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer. 2017 , 6, e1249561	161
935	Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1. 2017 , 23, 1920-1928	698
934	Gene-expression profiling to predict responsiveness to immunotherapy. 2017 , 24, 134-140	55
933	Beyond Seed and Soil: Understanding and Targeting Metastatic Prostate Cancer; Report From the 2016 Coffey-Holden Prostate Cancer Academy Meeting. 2017 , 77, 123-144	4
932	TNF α blockade overcomes resistance to anti-PD-1 in experimental melanoma. <i>Nature Communications</i> , 2017 , 8, 2256	17.4 175
931	Case report on the role of radiofrequency-assisted spleen-preserving surgery for splenic metastasis in the era of check-point inhibitors. 2017 , 96, e9106	5
930	Melanoma: Genetic Abnormalities, Tumor Progression, Clonal Evolution and Tumor Initiating Cells. 2017 , 5,	14
929	HisgAtlas 1.0: a human immunosuppression gene database. 2017 , 2017,	17
928	Telomere Dynamics in Immune Senescence and Exhaustion Triggered by Chronic Viral Infection. 2017 , 9,	68
927	TIM-3 as a Target for Cancer Immunotherapy and Mechanisms of Action. 2017 , 18,	122

926	The influence of radiation in the context of developing combination immunotherapies in cancer. 2017 , 5, 115-122	9
925	Local Immune Responsiveness of Mice Bearing Premalignant Oral Lesions to PD-1 Antibody Treatment. 2017 , 9,	6
924	Secretion of IFN- γ Associated with Galectin-9 Production by Pleural Fluid Cells from a Patient with Extrapulmonary Tuberculosis. 2017 , 18,	9
923	Coinhibitory Receptor Expression and Immune Checkpoint Blockade: Maintaining a Balance in CD8 T Cell Responses to Chronic Viral Infections and Cancer. 2017 , 8, 1215	55
922	The Potential of Donor T-Cell Repertoires in Neoantigen-Targeted Cancer Immunotherapy. 2017 , 8, 1718	23
921	Immune Checkpoints in Leprosy: Immunotherapy As a Feasible Approach to Control Disease Progression. 2017 , 8, 1724	3
920	Radiation enhanced the local and distant anti-tumor efficacy in dual immune checkpoint blockade therapy in osteosarcoma. 2017 , 12, e0189697	30
919	PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy. 2017 , 10, 146	57
918	Aktuelle Immuntherapien des malignen Melanoms. 2017 , 20, 16-20	
917	Immune Checkpoint Blockade and Adaptive Immune Resistance in Cancer. 2017 ,	1
916	Autophagic Mechanism in Anti-Cancer Immunity: Its Pros and Cons for Cancer Therapy. 2017 , 18,	24
915	Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade. 2017 , 8, 110693-110707	75
914	Immunotherapy for malignant pleural mesothelioma: current status and future directions. 2017 , 6, 315-324	24
913	Immune checkpoint blockade combined with IL-6 and TGF- β inhibition improves the therapeutic outcome of mRNA-based immunotherapy. 2018 , 143, 686-698	21
912	Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells. 2018 ,	8
911	PD-L1 inhibition with avelumab for metastatic Merkel cell carcinoma. 2018 , 11, 345-359	18
910	Importance of immune monitoring approaches and the use of immune checkpoints for the treatment of diffuse intrinsic pontine glioma: From bench to clinic and vice versa (Review). 2018 , 52, 1041-1056	4
909	Characterization of TIM-3 expression and its prognostic value in patients with surgically resected lung adenocarcinoma. 2018 , 121, 18-24	19

908	Immunotherapy for Glioblastoma: Playing Chess, Not Checkers. 2018 , 24, 4059-4061	10
907	Self-Delivering RNAi Targeting PD-1 Improves Tumor-Specific T Cell Functionality for Adoptive Cell Therapy of Malignant Melanoma. 2018 , 26, 1482-1493	29
906	T Cell Dysfunction in Cancer. 2018 , 33, 547-562	446
905	Bispecific antibodies in cancer immunotherapy. 2018 , 6, 3-17	104
904	Current state of immunotherapy for glioblastoma. 2018 , 15, 422-442	466
903	Tumor cell-intrinsic Tim-3 promotes liver cancer via NF- κ B/IL-6/STAT3 axis. 2018 , 37, 2456-2468	38
902	Molecular and clinical characterization of IDH associated immune signature in lower-grade gliomas. 2018 , 7, e1434466	23
901	Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa. 2018 , 15, 310-324	234
900	Repurposing Tin Mesoporphyrin as an Immune Checkpoint Inhibitor Shows Therapeutic Efficacy in Preclinical Models of Cancer. 2018 , 24, 1617-1628	24
899	TUSC2 Immunogene Therapy Synergizes with Anti-PD-1 through Enhanced Proliferation and Infiltration of Natural Killer Cells in Syngeneic -Mutant Mouse Lung Cancer Models. 2018 , 6, 163-177	12
898	T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma. 2018 , 24, 4175-4186	223
897	Strategies to activate NK cells to prevent relapse and induce remission following hematopoietic stem cell transplantation. 2018 , 131, 1053-1062	76
896	Mechanisms of Resistance to PD-1 and PD-L1 Blockade. 2018 , 24, 47-53	170
895	Molecular Biomarkers of Primary and Acquired Resistance to T-Cell-Mediated Immunotherapy in Cancer: Landscape, Clinical Implications, and Future Directions. 2018 , 23, 410-421	15
894	NK Cell-Based Therapies. 2018 , 275-288	1
893	Immunophenotyping of pediatric brain tumors: correlating immune infiltrate with histology, mutational load, and survival and assessing clonal T cell response. 2018 , 137, 269-278	23
892	Mechanisms of resistance to immune checkpoint inhibitors. 2018 , 118, 9-16	576
891	Radiotherapy and anti-PD-1/PD-L1 combinations in lung cancer: building better translational research platforms. 2018 , 29, 301-310	56

890	Lessons learned from the blockade of immune checkpoints in cancer immunotherapy. 2018 , 11, 31	141
889	Gut microbiome modulates efficacy of immune checkpoint inhibitors. 2018 , 11, 47	76
888	A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure. 2018 , 24, 3519-3527	49
887	[Tim-3: a novel biomarker and therapeutic target in oncology]. 2018 , 34, 231-237	0
886	PD-L1-Independent Mechanisms Control the Resistance of Melanoma to CD4 T Cell Adoptive Immunotherapy. 2018 , 200, 3304-3311	4
885	B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity. 2018 , 24, 2653-2664	57
884	Hyperprogressive Disease and Early Hypereosinophilia After Anti-PD-1 Treatment: A Case Report. 2018 , 5, 12	11
883	Armed oncolytic viruses: A kick-start for anti-tumor immunity. 2018 , 41, 28-39	72
882	Pseudoprogression and hyperprogression after checkpoint blockade. 2018 , 58, 125-135	89
881	Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies. 2018 , 48, 417-433	267
880	Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma. 2018 , 24, 4771-4784	21
879	Biomarker use in lung cancer management: expanding horizons. 2018 , 12, 315-320	0
878	High numbers of PDCD1 (PD-1)-positive T cells and mutations in microsatellite-unstable colorectal cancer. 2018 , 7, e1390640	26
877	Clinical decision-making for immunotherapy in metastatic renal cell carcinoma. 2018 , 28, 29-34	6
876	Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. 2018 , 359, 91-97	2203
875	Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells. 2018 , 96, 21-33	138
874	CD4 and CD8 T lymphocyte interplay in controlling tumor growth. 2018 , 75, 689-713	208
873	Emerging targets in cancer immunotherapy. 2018 , 52, 39-52	164

872	Blockade of Tim-3 binding to phosphatidylserine and CEACAM1 is a shared feature of anti-Tim-3 antibodies that have functional efficacy. 2018 , 7, e1385690	47
871	Prostate cancer immunotherapy: where are we and where are we going?. 2018 , 28, 15-24	30
870	Long non-coding RNA AGER-1 functionally upregulates the innate immunity gene AGER and approximates its anti-tumor effect in lung cancer. 2018 , 57, 305-318	22
869	Lack of MHC class II molecules favors CD8 T-cell infiltration into tumors associated with an increased control of tumor growth. 2018 , 7, e1404213	9
868	Delivering Type I Interferon to Dendritic Cells Empowers Tumor Eradication and Immune Combination Treatments. 2018 , 78, 463-474	47
867	Anti-Programmed Cell Death 1/Ligand 1 (PD-1/PD-L1) Antibodies for the Treatment of Urothelial Carcinoma: State of the Art and Future Development. 2018 , 16, 117-129	21
866	Immune checkpoint molecules soluble program death ligand 1 and galectin-9 are increased in pregnancy. 2018 , 79, e12795	52
865	Haploidentical natural killer cells induce remissions in non-Hodgkin lymphoma patients with low levels of immune-suppressor cells. 2018 , 67, 483-494	46
864	Molecular and Genomic Determinants of Response to Immune Checkpoint Inhibition in Cancer. 2018 , 69, 333-347	28
863	CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation. 2018 , 8, 216-233	308
862	Primer on Cancer Immunotherapy and the Targeting of Native Proteins. 2018 , 1-28	
861	Thoracic Immunotherapy. 2018 , 281-305	
860	TGFβ pathway inhibition in the treatment of non-small cell lung cancer. 2018 , 184, 112-130	46
859	Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma. 2018 , 24, 1260-1270	164
858	A safe and highly efficient tumor-targeted type I interferon immunotherapy depends on the tumor microenvironment. 2018 , 7, e1398876	28
857	The Dynamic and Transient Immune Microenvironment in Locally Advanced Esophageal Adenocarcinoma Post Chemoradiation. 2018 , 268, 992-999	45
856	Immunotherapy for thoracic malignancies. 2018 , 34, 54-64	
855	Immune reprogramming via PD-1 inhibition enhances early-stage lung cancer survival. 2018 , 3,	27

- 854 Aktuelle Immuntherapien des malignen Melanoms. **2018**, 21, 44-51
- 853 Hyperprogressive disease in patients with non-small cell lung cancer on immunotherapy. **2018**, 10, 1124-1128 37
- 852 Increased serum levels of Galectin-9 in patients with chronic lymphocytic leukemia. **2019**, 17, 1019-1029 4
- 851 Future of anti-PD-1/PD-L1 applications: Combinations with other therapeutic regimens. **2018**, 30, 157-172 26
- 850 Immunotherapy for non-small cell lung cancers: biomarkers for predicting responses and strategies to overcome resistance. **2018**, 18, 1082 29
- 849 Immunogenomic Landscape Contributes to Hyperprogressive Disease after Anti-PD-1 Immunotherapy for Cancer. **2018**, 9, 258-277 51
- 848 Acquired mechanisms of immune escape in cancer following immunotherapy. **2018**, 10, 87 26
- 847 VβVβ T Cells as Strategic Weapons to Improve the Potency of Immune Checkpoint Blockade and Immune Interventions in Human Myeloma. **2018**, 8, 508 8
- 846 The Identification of Immunological Biomarkers in Kidney Cancers. **2018**, 8, 456 32
- 845 Cryotherapy for nodal metastasis in NSCLC with acquired resistance to immunotherapy. **2018**, 6, 147 7
- 844 Crosstalk Between PD-1/PD-L1 Blockade and Its Combinatorial Therapies in Tumor Immune Microenvironment: A Focus on HNSCC. **2018**, 8, 532 17
- 843 Tumour associated lymphocytes in the pleural effusions of patients with mesothelioma express high levels of inhibitory receptors. **2018**, 11, 864 6
- 842 The immune checkpoint, HVEM may contribute to immune escape in non-small cell lung cancer lacking PD-L1 expression. **2018**, 125, 115-120 16
- 841 Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma. **2018**, 13, 599-609 12
- 840 Predictive and on-treatment monitoring biomarkers in advanced melanoma: Moving toward personalized medicine. **2018**, 71, 8-18 36
- 839 Prognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New Evidences. **2018**, 9, 1050 31
- 838 CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance. **2018**, 9, 2134 128
- 837 Combination immuno-oncology therapy with immune checkpoint blockers targeting PD-L1, PD-1 or CTLA4 and epigenetic drugs targeting MYC and immune evasion for precision medicine. **2018**, 10, 1294-1299 3

836	Checkpoint Inhibition: Will Combination with Radiotherapy and Nanoparticle-Mediated Delivery Improve Efficacy?. 2018 , 5,	11
835	Current frontline approaches in the management of hepatocellular carcinoma: the evolving role of immunotherapy. 2018 , 11, 1756284818808086	8
834	Next generation immune-checkpoints for cancer therapy. 2018 , 10, S1581-S1601	38
833	Hyperprogressive disease: recognizing a novel pattern to improve patient management. 2018 , 15, 748-762	206
832	Tim-3 expression and its role in hepatocellular carcinoma. 2018 , 11, 126	55
831	The challenges of checkpoint inhibition in the treatment of multiple myeloma. 2018 , 334, 87-98	10
830	Disruption of PD-1 Enhanced the Anti-tumor Activity of Chimeric Antigen Receptor T Cells Against Hepatocellular Carcinoma. 2018 , 9, 1118	82
829	TIM-3, a promising target for cancer immunotherapy. 2018 , 11, 7005-7009	107
828	T Cell-Inflamed versus Non-T Cell-Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection. 2018 , 6, 990-1000	188
827	Immune Checkpoint Inhibitors: Toward New Paradigms in Renal Cell Carcinoma. 2018 , 78, 1443-1457	41
826	Immune Checkpoint Inhibition in Head and Neck Cancer. 2018 , 8, 310	69
825	Quantitative Analyses of the Tumor Microenvironment Composition and Orientation in the Era of Precision Medicine. 2018 , 8, 390	31
824	sLAG-3 in non-small-cell lung cancer patients' serum. 2018 , 11, 4781-4784	12
823	The Antitumor Activity of Combinations of Cytotoxic Chemotherapy and Immune Checkpoint Inhibitors Is Model-Dependent. 2018 , 9, 2100	46
822	Small-Molecule Immune Checkpoint Inhibitors Targeting PD-1/PD-L1 and Other Emerging Checkpoint Pathways. 2018 , 32, 481-497	51
821	A comprehensive review on the role of co-signaling receptors and Treg homeostasis in autoimmunity and tumor immunity. 2018 , 95, 77-99	77
820	Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies. 2018 , 2018, 6984948	100
819	Immune Checkpoint Blockade and Immune Monitoring. 2018 ,	1

818	TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM. 2018 , 7, e1466769	133
817	Combined VEGF and PD-L1 Blockade Displays Synergistic Treatment Effects in an Autochthonous Mouse Model of Small Cell Lung Cancer. 2018 , 78, 4270-4281	72
816	Defining and Understanding Adaptive Resistance in Cancer Immunotherapy. 2018 , 39, 624-631	101
815	Keeping Tumors in Check: A Mechanistic Review of Clinical Response and Resistance to Immune Checkpoint Blockade in Cancer. 2018 , 430, 2014-2029	30
814	Emerging biomarkers for immune checkpoint inhibition in lung cancer. 2018 , 52, 269-277	54
813	Perspectives on Acquired Resistance to PD-1 Axis Inhibitors in Patients with Non-Small Cell Lung Cancer. 2018 , 13, 741-744	4
812	Aktuelle Immuntherapien des malignen Melanoms. 2018 , 34, 32-38	
811	The Immune Landscape of Non-Small-Cell Lung Cancer. Utility of Cytologic and Histologic Samples Obtained through Minimally Invasive Pulmonary Procedures. 2018 , 198, 24-38	11
810	CRISPR/Cas9-Mediated Knockout of DGK Improves Antitumor Activities of Human T Cells. 2018 , 78, 4692-4703	92
809	Indoleamine 2,3-dioxygenase provides adaptive resistance to immune checkpoint inhibitors in hepatocellular carcinoma. 2018 , 67, 1305-1315	61
808	Monitoring Immune Checkpoint Regulators as Predictive Biomarkers in Hepatocellular Carcinoma. 2018 , 8, 269	69
807	Immune oncology, immune responsiveness and the theory of everything. 2018 , 6, 50	40
806	Immune Checkpoint-Mediated Interactions Between Cancer and Immune Cells in Prostate Adenocarcinoma and Melanoma. 2018 , 9, 1786	14
805	Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion. 2018 , 9, 536	124
804	Incorporation of Immune Checkpoint Blockade into Chimeric Antigen Receptor T Cells (CAR-Ts): Combination or Built-In CAR-T. 2018 , 19,	105
803	Toward Biomaterials for Enhancing Immune Checkpoint Blockade Therapy. 2018 , 28, 1802540	69
802	Resistance to Radiotherapy and PD-L1 Blockade Is Mediated by TIM-3 Upregulation and Regulatory T-Cell Infiltration. 2018 , 24, 5368-5380	120
801	The evolving immunotherapeutic landscape in advanced oesophagogastric cancer. 2018 , 10, 1758835918786228	

800	Checks and Balances in Autoimmune Vasculitis. 2018 , 9, 315	23
799	Improving the Efficiency of VβVβ T-Cell Immunotherapy in Cancer. 2018 , 9, 800	67
798	Concepts Collide: Genomic, Immune, and Microbial Influences on the Tumor Microenvironment and Response to Cancer Therapy. 2018 , 9, 946	13
797	VβVβ T Cells in the Bone Marrow of Myeloma Patients: A Paradigm of Microenvironment-Induced Immune Suppression. 2018 , 9, 1492	10
796	Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations. 2018 , 8, 86	529
795	Indoleamine 2,3-dioxygenase 1 and programmed cell death-ligand 1 co-expression correlates with aggressive features in lung adenocarcinoma. 2018 , 101, 20-29	23
794	The Role of Inflammatory Cytokines in Creating T Cell Exhaustion in Cancer. 2018 , 33, 267-273	7
793	Dual TGF-β and PD-1 blockade synergistically enhances MAGE-A3-specific CD8 T cell response in esophageal squamous cell carcinoma. 2018 , 143, 2561-2574	49
792	Role of Galectins in Tumors and in Clinical Immunotherapy. 2018 , 19,	109
791	Cancer Immunotherapy: A Focus on the Regulation of Immune Checkpoints. 2018 , 19,	50
790	CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade. 2018 , 8, 1156-1175	195
789	Dual PD-1 and CTLA-4 Checkpoint Blockade Promotes Antitumor Immune Responses through CD4Foxp3 Cell-Mediated Modulation of CD103 Dendritic Cells. 2018 , 6, 1069-1081	38
788	Immunotherapy in non-small-cell lung cancer: a bridge between research and clinical practice. 2018 , 14, 41-60	7
787	Immune-checkpoint inhibitors in melanoma and kidney cancer: from sequencing to rational selection. 2018 , 10, 1758835918777427	5
786	Toward innovative combinational immunotherapy: A systems biology perspective. 2018 , 68, 1-8	11
785	Indoleamine 2,3-dioxygenase 1 inhibition targets anti-PD1-resistant lung tumors by blocking myeloid-derived suppressor cells. 2018 , 431, 54-63	35
784	Future prospects of immune checkpoint blockade in cancer: from response prediction to overcoming resistance. 2018 , 50, 1-13	105
783	Targeting the PD-1/PD-L1 axis for the treatment of non-small-cell lung cancer. 2018 , 25, e324-e334	38

- 782 Present and future of cancer immunotherapy: A tumor microenvironmental perspective. **2018**, 16, 4105-4113 51
- 781 The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC. **2018**, 12, 981-986 25
- 780 Drug response to PD-1/PD-L1 blockade: based on biomarkers. **2018**, 11, 4673-4683 33
- 779 Increased Tim-3 T cells in PBMCs during nivolumab therapy correlate with responses and prognosis of advanced esophageal squamous cell carcinoma patients. **2018**, 67, 1673-1683 20
- 778 Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer. **2018**, 11, 43 39
- 777 Immune checkpoint therapy in liver cancer. **2018**, 37, 110 123
- 776 Dysfunction of HPV16-specific CD8+ T cells derived from oropharyngeal tumors is related to the expression of Tim-3 but not PD-1. **2018**, 82, 75-82 11
- 775 A Multifunctional Biomimetic Nanoplatfom for Relieving Hypoxia to Enhance Chemotherapy and Inhibit the PD-1/PD-L1 Axis. **2018**, 14, e1801120 87
- 774 Cancer immunotherapy: broadening the scope of targetable tumours. **2018**, 8, 67
- 773 Harnessing Tumor Evolution to Circumvent Resistance. **2018**, 34, 639-651 32
- 772 Acquired resistance to cancer immunotherapy. **2019**, 41, 31-40 18
- 771 To do or not to do: A concise update of current clinical controversies in immune checkpoint blockade. **2019**, 25, 663-673 7
- 770 On the Horizon: Targeting Next-Generation Immune Checkpoints for Cancer Treatment. **2019**, 64, 62-80 26
- 769 PD-1 silencing impairs the anti-tumor function of chimeric antigen receptor modified T cells by inhibiting proliferation activity. **2019**, 7, 209 41
- 768 Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors. **2019**, 36, 2638-2678 86
- 767 Mechanisms of immunotherapy resistance: lessons from glioblastoma. **2019**, 20, 1100-1109 189
- 766 Tumor-induced escape mechanisms and their association with resistance to checkpoint inhibitor therapy. **2019**, 68, 1689-1700 45
- 765 Hyperprogression after immunotherapy in patients with malignant tumors of digestive system. **2019**, 19, 705 17

764	The Role of Biomarkers for the Prediction of Response to Checkpoint Immunotherapy and the Rationale for the Use of Checkpoint Immunotherapy in Cervical Cancer. 2019 , 31, 834-843	29
763	Cas9-edited immune checkpoint blockade PD-1 DNA polyaptamer hydrogel for cancer immunotherapy. 2019 , 218, 119359	25
762	Gal9/Tim-3 expression level is higher in AML patients who fail chemotherapy. 2019 , 7, 175	35
761	Contributions of T cell dysfunction to the resistance against anti-PD-1 therapy in oral carcinogenesis. 2019 , 38, 299	15
760	Personalized medicine: From diagnostic to adaptive.. 2022 , 45, 132-142	2
759	New emerging targets in cancer immunotherapy: the role of TIM3. 2019 , 4, e000497	49
758	Optimizing oncolytic virotherapy in cancer treatment. 2019 , 18, 689-706	198
757	Immunotherapies for the Treatment of Uveal Melanoma-History and Future. 2019 , 11,	34
756	T Cell Dysfunction in Cancer Immunity and Immunotherapy. 2019 , 10, 1719	121
755	Changes in Expression of Multiple Checkpoint Molecules and Infiltration of Tumor Immune Cells after Neoadjuvant Chemotherapy in Gastric Cancer. 2019 , 10, 2754-2763	21
754	Reprogramming lymphocytes for the treatment of melanoma: From biology to therapy. 2019 , 141, 104-124	10
753	Expression of lymphocyte immunoregulatory biomarkers in bone and soft-tissue sarcomas. 2019 , 32, 1772-1785	33
752	Challenges and strategies for successful clinical development of immune checkpoint inhibitors in glioblastoma. 2019 , 20, 1609-1624	5
751	Development of a novel human phage display-derived anti-LAG3 scFv antibody targeting CD8 T lymphocyte exhaustion. 2019 , 19, 67	6
750	Adoptive cell therapy with tumour-infiltrating lymphocytes: the emerging importance of clonal neoantigen targets for next-generation products in non-small cell lung cancer. 2019 , 3, 1-7	8
749	Immune checkpoint protein and cytokine expression by T lymphocytes in pleural effusion of cancer patients receiving anti-PD-1 therapy. 2019 , 138, 58-64	2
748	Breast Cancer Cells and PD-1/PD-L1 Blockade Upregulate the Expression of PD-1, CTLA-4, TIM-3 and LAG-3 Immune Checkpoints in CD4 T Cells. 2019 , 7,	30
747	Tim-3: A co-receptor with diverse roles in T cell exhaustion and tolerance. 2019 , 42, 101302	50

746	Monoclonal Antibodies in Dermatooncology-State of the Art and Future Perspectives. 2019 , 11,	6
745	Glycogen synthase 3 (GSK-3) regulation of PD-1 expression and and its therapeutic implications. 2019 , 42, 101295	8
744	Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. 2019 , 18, 155	353
743	If we build it they will come: targeting the immune response to breast cancer. 2019 , 5, 37	76
742	Does selected immunological panel possess the value of predicting the prognosis of early-stage resectable non-small cell lung cancer?. 2019 , 8, 559-574	5
741	A Comprehensive Analysis of Key Immune Checkpoint Receptors on Tumor-Infiltrating T Cells From Multiple Types of Cancer. 2019 , 9, 1066	30
740	Targeting Negative and Positive Immune Checkpoints with Monoclonal Antibodies in Therapy of Cancer. 2019 , 11,	53
739	Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors. 2019 , 36, 471-482	139
738	PD-1 and LAG-3 Dominate Checkpoint Receptor-Mediated T-cell Inhibition in Renal Cell Carcinoma. 2019 , 7, 1891-1899	31
737	Targeting the Immune Microenvironment in the Treatment of Head and Neck Squamous Cell Carcinoma. 2019 , 9, 1084	39
736	Exploiting NK Cell Surveillance Pathways for Cancer Therapy. 2019 , 11,	23
735	Impressive response to nivolumab of non-small-cell lung cancer containing sarcomatoid components. 2019 , 7, e00477	6
734	Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade. 2019 , 29, 846-861	91
733	The current state of immunotherapy for gliomas: an eye toward the future. 2019 , 131, 657-666	48
732	Achievements and futures of immune checkpoint inhibitors in non-small cell lung cancer. 2019 , 8, 19	23
731	Peripheral changes in immune cell populations and soluble mediators after anti-PD-1 therapy in non-small cell lung cancer and renal cell carcinoma patients. 2019 , 68, 1585-1596	19
730	Overcoming Immunological Resistance Enhances the Efficacy of A Novel Anti-tMUC1-CAR T Cell Treatment against Pancreatic Ductal Adenocarcinoma. 2019 , 8,	23
729	Melanoma plasticity and phenotypic diversity: therapeutic barriers and opportunities. 2019 , 33, 1295-1318	89

728	The innate immune architecture of lung tumors and its implication in disease progression. 2019 , 247, 589-605	24
727	Clonal Deletion of Tumor-Specific T Cells by Interferon- γ Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade. 2019 , 50, 477-492.e8	56
726	Intrinsic cancer vaccination. 2019 , 151-152, 2-22	18
725	Liquid biopsy for lung cancer immunotherapy. 2019 , 17, 4751-4760	8
724	Expression of costimulatory and inhibitory receptors in FoxP3 regulatory T cells within the tumor microenvironment: Implications for combination immunotherapy approaches. 2019 , 144, 193-261	9
723	Molecular Mechanisms and Countermeasures of Immunotherapy Resistance in Malignant Tumor. 2019 , 10, 1764-1771	9
722	The 6th R of Radiobiology: Reactivation of Anti-Tumor Immune Response. 2019 , 11,	33
721	A good start of immunotherapy in esophageal cancer. 2019 , 8, 4519-4526	31
720	Molecular and clinical characterization of TMEM71 expression at the transcriptional level in glioma. 2019 , 25, 965-975	11
719	PD-1 Dynamically Regulates Inflammation and Development of Brain-Resident Memory CD8 T Cells During Persistent Viral Encephalitis. 2019 , 10, 783	19
718	Neue Therapieansätze beim metastasierten Nierenzellkarzinom. 2019 , 25, 523-528	
717	Exceptional pemetrexed sensitivity can predict therapeutic benefit from subsequent chemotherapy in metastatic non-squamous non-small cell lung cancer. 2019 , 145, 1897-1905	3
716	Monitoring Patient Response to Pembrolizumab With Peripheral Blood Exhaustion Marker Profiles. 2019 , 6, 113	13
715	Biomarkers for Immune Checkpoint Inhibitor-Mediated Tumor Response and Adverse Events. 2019 , 6, 119	83
714	LNK suppresses interferon signaling in melanoma. <i>Nature Communications</i> , 2019 , 10, 2230	17.4 8
713	Innate Immune Cells: A Potential and Promising Cell Population for Treating Osteosarcoma. 2019 , 10, 1114	24
712	Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. 2019 , 7, 131	41
711	A Career in Lung Cancer: Pushing Beyond Chemotherapy. 2019 , 39, 583-589	1

710	Research progress and clinical application of predictive biomarker for immune checkpoint inhibitors. 2019 , 19, 517-529	8
709	My journey from tyrosine phosphorylation inhibitors to targeted immune therapy as strategies to combat cancer. 2019 , 116, 11579-11586	9
708	Treg-mediated acquired resistance to immune checkpoint inhibitors. 2019 , 457, 168-179	81
707	NK cells to cure cancer. 2019 , 41, 101272	38
706	Human Pancreatic Carcinoma-Associated Fibroblasts Promote Expression of Co-inhibitory Markers on CD4 and CD8 T-Cells. 2019 , 10, 847	59
705	Hypoxia-Induced VISTA Promotes the Suppressive Function of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment. 2019 , 7, 1079-1090	75
704	Biohybrid Vaccines for Improved Treatment of Aggressive Melanoma with Checkpoint Inhibitor. 2019 , 13, 6477-6490	29
703	Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?. 2019 , 39, 147-164	248
702	Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches. 2019 , 249, 151-165	35
701	Update on Mechanisms of Adaptive Resistance to Immune Check Point Blockers in Malignancies: A Short Commentary. 2018 , 24, 5349-5351	1
700	Pan-cancer genomic analysis links 3'UTR DNA methylation with increased gene expression in T cells. 2019 , 43, 127-137	18
699	Innate Lymphoid Cells: Expression of PD-1 and Other Checkpoints in Normal and Pathological Conditions. 2019 , 10, 910	40
698	Ntrk1 Promotes Resistance to PD-1 Checkpoint Blockade in Mesenchymal Kras/p53 Mutant Lung Cancer. 2019 , 11,	14
697	Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies. 2019 , 12, 42	35
696	Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma. 2019 , 10, 453	114
695	Immunological and clinical implications of immune checkpoint blockade in human cancer. 2019 , 42, 567-581	10
694	Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes. 2019 , 25, 4592-4602	241
693	PD-1/PD-L1 blockade in cervical cancer: current studies and perspectives. 2019 , 13, 438-450	17

692	Immunoglobulin Gamma-Like Therapeutic Bispecific Antibody Formats for Tumor Therapy. 2019 , 2019, 4516041	5
691	The mucin-selective protease StcE enables molecular and functional analysis of human cancer-associated mucins. 2019 , 116, 7278-7287	103
690	Targeting late-stage non-small cell lung cancer with a combination of DNT cellular therapy and PD-1 checkpoint blockade. 2019 , 38, 123	12
689	Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer. 2019 , 216, 982-1000	105
688	Microbiome and Cancers, With Focus on Genitourinary Tumors. 2019 , 9, 178	10
687	mTOR Signalling in Head and Neck Cancer: Heads Up. 2019 , 8,	26
686	TIM-3 in endometrial carcinomas: an immunotherapeutic target expressed by mismatch repair-deficient and intact cancers. 2019 , 32, 1168-1179	13
685	PD-1/PD-L1 Combinations in Advanced Urothelial Cancer: Rationale and Current Clinical Trials. 2019 , 17, e618-e626	8
684	Immune profiling reveals the diverse nature of the immune response in NSCLC and reveals signaling pathways that may influence the anti-tumor immune response. 2019 , 109, 1-15	3
683	Immunotherapy in Multiple Myeloma: Accelerating on the Path to the Patient. 2019 , 19, 332-344	13
682	Recent Advances in Polymeric Nanomedicines for Cancer Immunotherapy. 2019 , 8, e1801320	25
681	FcR-Binding Is an Important Functional Attribute for Immune Checkpoint Antibodies in Cancer Immunotherapy. 2019 , 10, 292	58
680	Targeting Immune Checkpoints in Lung Cancer: Current Landscape and Future Prospects. 2019 , 39, 341-353	13
679	Prevalence and Cellular Distribution of Novel Immune Checkpoint Targets Across Longitudinal Specimens in Treatment-naïve Melanoma Patients: Implications for Clinical Trials. 2019 , 25, 3247-3258	15
678	The pioneers behind immune checkpoint blockers awarded the Nobel Prize in physiology or medicine 2018. 2019 , 58, 1-8	14
677	Recent success and limitations of immune checkpoint inhibitors for cancer: a lesson from melanoma. 2019 , 474, 421-432	28
676	Hyperprogression after immunotherapy. 2019 , 8, 244-246	7
675	Recent advances in nanosized drug delivery systems for overcoming the barriers to anti-PD immunotherapy of cancer. 2019 , 29, 100801	37

674	c-Cbl targets PD-1 in immune cells for proteasomal degradation and modulates colorectal tumor growth. 2019 , 9, 20257	16
673	Harnessing NK Cells for Cancer Treatment. 2019 , 10, 2836	44
672	Significance of TIM3 expression in cancer: From biology to the clinic. 2019 , 46, 372-379	28
671	CAR T Cells: A Snapshot on the Growing Options to Design a CAR. 2019 , 3, e172	21
670	Syngeneic animal models of tobacco-associated oral cancer reveal the activity of in situ anti-CTLA-4. <i>Nature Communications</i> , 2019 , 10, 5546	17.4 53
669	Prognostic and diagnostic significance of galectins in pancreatic cancer: a systematic review and meta-analysis. 2019 , 19, 309	10
668	Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups. 2019 , 20, 1425-1434	177
667	Immunologic Features of Patients With Advanced Hepatocellular Carcinoma Before and During Sorafenib or Anti-programmed Death-1/Programmed Death-L1 Treatment. 2019 , 10, e00058	21
666	[CD38 antibodies in multiple myeloma]. 2019 , 35, 1001-1004	0
665	Acquired Mutation Drives Immune Checkpoint Inhibitor-Acquired Resistance in a Microsatellite Instability-High Gastroesophageal Adenocarcinoma With Brain Metastases.. 2019 , 3, 1-6	1
664	Immunomodulators targeting the PD-1/PD-L1 protein-protein interaction: From antibodies to small molecules. 2019 , 39, 265-301	85
663	Data Rich, Information Poor: Can We Use Electronic Health Records to Create a Learning Healthcare System for Pharmaceuticals?. 2019 , 105, 912-922	48
662	Immune Checkpoints. 2019 , 19-43	
661	The Current Status of Immunotherapy in Thoracic Malignancies. 2019 , 45-75	
660	Future of Immune Checkpoint Inhibitors. 2019 , 227-243	2
659	Rational combination of cancer immunotherapy in melanoma. 2019 , 474, 433-447	6
658	TSR-033, a Novel Therapeutic Antibody Targeting LAG-3, Enhances T-Cell Function and the Activity of PD-1 Blockade and. 2019 , 18, 632-641	27
657	Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. 2019 , 18, 197-218	981

656	Immunotherapy for gastric cancer: dilemmas and prospect. 2019 , 18, 107-112	34
655	Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma. 2019 , 30, 57-67	83
654	Hyperprogressive disease in hepatocellular carcinoma with immune checkpoint inhibitor use: a case series. 2019 , 11, 167-175	21
653	Immune checkpoint blockade for Merkel cell carcinoma: actual findings and unanswered questions. 2019 , 145, 429-443	8
652	Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer. 2019 , 22, 793-802	76
651	In situ vaccination with biocompatibility controllable immuno-sensitizer inducing antitumor immunity. 2019 , 197, 32-40	11
650	Inhibitory functions of PD-L1 and PD-L2 in the regulation of anti-tumor immunity in murine tumor microenvironment. 2019 , 68, 201-211	28
649	A SERS microfluidic platform for targeting multiple soluble immune checkpoints. 2019 , 126, 178-186	32
648	The Effectiveness of Checkpoint Inhibitor Combinations and Administration Timing Can Be Measured by Granzyme B PET Imaging. 2019 , 25, 1196-1205	52
647	The lung microenvironment: an important regulator of tumour growth and metastasis. 2019 , 19, 9-31	347
646	Long-Term Survival in Patients Responding to Anti-PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation. 2019 , 25, 946-956	67
645	Mechanisms of Resistance to Immune Checkpoint Blockade. 2019 , 20, 41-54	51
644	Interferon γ and Its Important Roles in Promoting and Inhibiting Spontaneous and Therapeutic Cancer Immunity. 2019 , 11,	138
643	Addressing barriers to effective cancer immunotherapy with nanotechnology: achievements, challenges, and roadmap to the next generation of nanoimmunotherapeutics. 2019 , 141, 3-22	26
642	Cancer Immunology. 2020 , 84-96.e5	
641	Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses. 2020 , 10, 723-733	38
640	Nivolumab induces dynamic alterations in CD8 T-cell function and TIM-3 expression when used to treat relapsed acute myeloid leukemia after allogeneic stem cell transplantation. 2020 , 61, 185-188	1
639	Immune checkpoints in the tumor microenvironment. 2020 , 65, 1-12	62

638	Acquired resistance to cancer immunotherapy: Role of tumor-mediated immunosuppression. 2020 , 65, 13-27	85
637	Biological regulation of diacylglycerol kinases in normal and neoplastic tissues: New opportunities for cancer immunotherapy. 2020 , 75, 100663	8
636	TIM3 comes of age as an inhibitory receptor. 2020 , 20, 173-185	211
635	Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer. 2020 , 1, 99-111	67
634	Transposon-mediated generation of CAR-T cells shows efficient anti B-cell leukemia response after ex vivo expansion. 2020 , 27, 85-95	13
633	Oncogenic signaling pathways associated with immune evasion and resistance to immune checkpoint inhibitors in cancer. 2020 , 65, 51-64	35
632	Overcoming malignant cell-based mechanisms of resistance to immune checkpoint blockade antibodies. 2020 , 65, 28-37	7
631	Combining Doxorubicin-Loaded PEGylated Poly(Lactide-co-glycolide) Nanoparticles with Checkpoint Inhibition Safely Enhances Therapeutic Efficacy in a Melanoma Model. 2020 , 6, 2659-2667	9
630	Brain immunology and immunotherapy in brain tumours. 2020 , 20, 12-25	174
629	Primary and acquired resistance mechanisms to immune checkpoint inhibition in Hodgkin lymphoma. 2020 , 82, 101931	20
628	4-1BB Agonism Averts TIL Exhaustion and Licenses PD-1 Blockade in Glioblastoma and Other Intracranial Cancers. 2020 , 26, 1349-1358	15
627	CAR T-Cell Therapy for CNS Malignancies. 2020 , 165-198	
626	Non-genetic mechanisms of therapeutic resistance in cancer. 2020 , 20, 743-756	94
625	Cooperation between chemotherapy and immunotherapy in gastroesophageal cancers. 2020 , 495, 89-99	10
624	The PD-1/PD-L1-Checkpoint Restrains T _H 1 Cell Immunity in Tumor-Draining Lymph Nodes. 2020 , 38, 685-700.e8	85
623	The biologically functional identification of a novel TIM3-binding peptide P26 in vitro and in vivo. 2020 , 86, 783-792	0
622	Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Status and Novel Perspectives. 2020 , 12,	28
621	Mechanisms of resistance to immune checkpoint inhibitors and strategies to reverse drug resistance in lung cancer. 2020 , 133, 2444-2455	3

620	Exploration of Feasible Immune Biomarkers for Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma Treatment in Real World Clinical Practice. 2020 , 21,	7
619	[Immunotherapy of metastatic non-small cell lung cancer from first line to resistance and its management]. 2020 , 107, 779-791	0
618	Common phenotypic dynamics of tumor-infiltrating lymphocytes across different histologies upon checkpoint inhibition: impact on clinical outcome. 2020 , 22, 204-213	2
617	An Antigen-Delivery Protein Nanoparticle Combined with Anti-PD-1 Checkpoint Inhibitor Has Curative Efficacy in an Aggressive Melanoma Model. 2020 , 3, 2000122	1
616	Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial. 2020 , 26, 5140-5152	71
615	Hyperprogressive disease and its clinical impact in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with immune-checkpoint inhibitors: Korean cancer study group HN 18-12. 2020 , 146, 3359-3369	5
614	Resistance to immune checkpoint inhibitors in non-small cell lung cancer: biomarkers and therapeutic strategies. 2020 , 12, 1758835920937902	13
613	Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies. 2020 , 53, 100718	52
612	Radiotherapy for non-small cell lung cancer in the immunotherapy era: the opportunity and challenge-a narrative review. 2020 , 9, 2120-2136	4
611	Immunotherapeutic Targets and Therapy for Renal Cell Carcinoma. 2020 , 9, 273-288	6
610	Immune Checkpoint Targeted Therapy in Glioma: Status and Hopes. 2020 , 11, 578877	24
609	Diacylglycerol kinase β limits IL-2-dependent control of PD-1 expression in tumor-infiltrating T lymphocytes. 2020 , 8,	3
608	Emerging Role of Extracellular Vesicles in Immune Regulation and Cancer Progression. 2020 , 12,	15
607	Targeting novel inhibitory receptors in cancer immunotherapy. 2020 , 49, 101436	3
606	The Role of TIM-3 in Hepatocellular Carcinoma: A Promising Target for Immunotherapy?. 2020 , 10, 601661	12
605	A novel antibody targeting TIM-3 resulting in receptor internalization for cancer immunotherapy. 2020 , 3, 227-236	5
604	Stresses in the metastatic cascade: molecular mechanisms and therapeutic opportunities. 2020 , 34, 1577-1598	4
603	Immune Checkpoints and CAR-T Cells: The Pioneers in Future Cancer Therapies?. 2020 , 21,	22

602	Roles for the FCRL6 Immunoreceptor in Tumor Immunology. 2020 , 11, 575175	5
601	Relaxin-expressing oncolytic adenovirus induces remodeling of physical and immunological aspects of cold tumor to potentiate PD-1 blockade. 2020 , 8,	14
600	Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors. 2020 , 8, 672	55
599	Clinical characteristics of hyperprogressive disease in NSCLC after treatment with immune checkpoint inhibitor: a systematic review and meta-analysis. 2020 , 20, 707	11
598	Progress in Neoantigen Targeted Cancer Immunotherapies. 2020 , 8, 728	12
597	Modulation of Determinant Factors to Improve Therapeutic Combinations with Immune Checkpoint Inhibitors. 2020 , 9,	4
596	Targeting immune checkpoints in hematological malignancies. 2020 , 13, 111	28
595	The tumor microenvironment of colorectal cancer metastases: opportunities in cancer immunotherapy. 2020 , 12, 1083-1100	11
594	Mechanisms of Cancer Resistance to Immunotherapy. 2020 , 10, 1290	53
593	Atypical response patterns in metastatic melanoma and renal cell carcinoma patients treated with nivolumab: A single center experience. 2021 , 27, 1106-1111	0
592	Immunotherapy in Hematologic Malignancies: Emerging Therapies and Novel Approaches. 2020 , 21,	10
591	Emerging immunotherapy targets in lung cancer. 2020 , 133, 2456-2465	4
590	Targeting TIM-3 in solid tumors: innovations in the preclinical and translational realm and therapeutic potential. 2020 , 24, 1251-1262	7
589	CXCR4 Inhibition Counteracts Immunosuppressive Properties of Metastatic NSCLC Stem Cells. 2020 , 11, 02168	7
588	TIM-3 Expression Is Downregulated on Human NK Cells in Response to Cancer Targets in Synergy with Activation. 2020 , 12,	11
587	The critical role of CD4+ T cells in PD-1 blockade against MHC-II-expressing tumors such as classic Hodgkin lymphoma. 2020 , 4, 4069-4082	31
586	Checkpoint inhibitor immunotherapy for glioblastoma: current progress, challenges and future outlook. 2020 , 13, 1147-1158	3
585	Resisting Resistance to Immune Checkpoint Therapy: A Systematic Review. 2020 , 21,	10

584	Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker. 2020 , 9, 8086-8121	34
583	Imaging the Cancer Immune Environment and Its Response to Pharmacologic Intervention, Part 2: The Role of Novel PET Agents. 2020 , 61, 1553-1559	7
582	Metabolic and epigenetic regulation of T-cell exhaustion. 2020 , 2, 1001-1012	47
581	Association of MUC16 Mutation With Response to Immune Checkpoint Inhibitors in Solid Tumors. 2020 , 3, e2013201	13
580	Profound Functional Suppression of Tumor-Infiltrating T-Cells in Ovarian Cancer Patients Can Be Reversed Using PD-1-Blocking Antibodies or DARPin \square Proteins. 2020 , 2020, 7375947	2
579	Carbon Dioxide Conversion with High-Performance Photocatalysis into Methanol on NiSe ₂ /WSe ₂ . 2020 , 13, 4330	1
578	Modulation of the Gut Microbiota Alters the Tumour-Suppressive Efficacy of Tim-3 Pathway Blockade in a Bacterial Species- and Host Factor-Dependent Manner. 2020 , 8,	2
577	EZH2 inhibition: a promising strategy to prevent cancer immune editing. 2020 , 12, 1457-1476	12
576	Mycosis fungoides development after combined immune checkpoint blockade therapy in a patient with malignant melanoma: a case report. 2020 , 30, 515-518	2
575	Melanoma Evolves Complete Immunotherapy Resistance through the Acquisition of a Hypermetabolic Phenotype. 2020 , 8, 1365-1380	13
574	Overcoming immunotherapy resistance in non-small cell lung cancer (NSCLC) - novel approaches and future outlook. 2020 , 19, 141	45
573	Targeting phosphatidylserine for Cancer therapy: prospects and challenges. 2020 , 10, 9214-9229	18
572	Immunotherapy for Glioblastoma: Current State, Challenges, and Future Perspectives. 2020 , 12,	4
571	The Evolving Knowledge on T and NK Cells in Classic Hodgkin Lymphoma: Insights into Novel Subsets Populating the Immune Microenvironment. 2020 , 12,	1
570	Acquired Resistance to PD-1/PD-L1 Blockade in Lung Cancer: Mechanisms and Patterns of Failure. 2020 , 12,	11
569	The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?. 2020 , 11, 574271	24
568	The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy. 2020 , 19, 81	34
567	New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma. 2020 , 51, 100702	32

566	Targeting PD-L1 Initiates Effective Antitumor Immunity in a Murine Model of Cushing Disease. 2020 , 26, 1141-1151	24
565	Acquired Resistance to Immune Checkpoint Blockade Therapies. 2020 , 12,	3
564	Targeting Myeloid-Derived Suppressor Cell, a Promising Strategy to Overcome Resistance to Immune Checkpoint Inhibitors. 2020 , 11, 783	43
563	Immune checkpoint pathways in immunotherapy for head and neck squamous cell carcinoma. 2020 , 12, 16	46
562	The future of cancer immunotherapy: microenvironment-targeting combinations. 2020 , 30, 507-519	194
561	The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies. 2020 , 11, 784	98
560	Targeting NK Cell Checkpoint Receptors or Molecules for Cancer Immunotherapy. 2020 , 11, 1295	26
559	Mechanisms of immune escape in the cancer immune cycle. 2020 , 86, 106700	28
558	Immune Checkpoint Inhibitors in Hepatocellular Cancer: Current Understanding on Mechanisms of Resistance and Biomarkers of Response to Treatment. 2020 , 20, 53-65	30
557	Can Ipilimumab restore immune response in advanced NSCLC after progression on anti-PD-1/PD-L1 agents?. 2020 , 11, 2331-2334	2
556	Role of Epigenetic Modifications in Inhibitory Immune Checkpoints in Cancer Development and Progression. 2020 , 11, 1469	21
555	Tumor microenvironmental influences on dendritic cell and T cell function: A focus on clinically relevant immunologic and metabolic checkpoints. 2020 , 10, 374-411	12
554	Molecular profiling of an osseous metastasis in glioblastoma during checkpoint inhibition: potential mechanisms of immune escape. 2020 , 8, 28	9
553	Immunotherapy in Multiple Myeloma. 2020 , 9,	18
552	How Can Immune Checkpoint Inhibitors Cause Hyperprogression in Solid Tumors?. 2020 , 11, 492	21
551	Modulation of tumor microenvironment for immunotherapy: focus on nanomaterial-based strategies. 2020 , 10, 3099-3117	34
550	Melanoma immunotherapy: strategies to overcome pharmacological resistance. 2020 , 20, 289-304	6
549	Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations. 2020 , 15, 914-947	71

548	Current Understanding of the Mechanisms Underlying Immune Evasion From PD-1/PD-L1 Immune Checkpoint Blockade in Head and Neck Cancer. 2020 , 10, 268	36
547	Tim-3 finds its place in the cancer immunotherapy landscape. 2020 , 8,	84
546	Comprehensive Analysis of PD-1 Gene Expression, Immune Characteristics and Prognostic Significance in 1396 Glioma Patients. 2020 , 12, 4399-4410	4
545	Immune Checkpoint Inhibition-Does It Cause Rheumatic Diseases? Mechanisms of Cancer-Associated Loss of Tolerance and Pathogenesis of Autoimmunity. 2020 , 46, 587-603	1
544	Translational Windows in Chordoma: A Target Appraisal. 2020 , 11, 657	2
543	New immunotherapeutic drugs in advanced non-small cell lung cancer (NSCLC): from preclinical to phase I clinical trials. 2020 , 29, 1005-1023	9
542	Molecular and clinical characterization of PARP9 in gliomas: A potential immunotherapeutic target. 2020 , 26, 804-814	9
541	Blockade of PD-1, PD-L1, and TIM-3 Altered Distinct Immune- and Cancer-Related Signaling Pathways in the Transcriptome of Human Breast Cancer Explants. 2020 , 11,	7
540	Successful continuous nivolumab therapy for metastatic non-small cell lung cancer after local treatment of oligometastatic lesions. 2020 , 11, 2357-2360	3
539	The 5-Ws of immunotherapy in head and neck cancer. 2020 , 153, 103041	7
538	Tryptophan Catabolism as Immune Mechanism of Primary Resistance to Anti-PD-1. 2020 , 11, 1243	13
537	The expression and immunoregulation of immune checkpoint molecule VISTA in autoimmune diseases and cancers. 2020 , 52, 1-14	7
536	Checkpoint molecules coordinately restrain hyperactivated effector T cells in the tumor microenvironment. 2020 , 9, 1708064	11
535	Unleashing Natural Killer Cells in the Tumor Microenvironment-The Next Generation of Immunotherapy?. 2020 , 11, 275	56
534	Mechanisms of Resistance to PD-1 Checkpoint Blockade. 2020 , 80, 459-465	4
533	Landscape of Immune Checkpoint Inhibition in Carcinosarcoma (MMMT): Analysis of IDO-1, PD-L1 and PD-1. 2020 , 216, 152847	5
532	Resistance to Checkpoint Inhibition in Cancer Immunotherapy. 2020 , 13, 100738	91
531	Highly efficient and tumor-selective nanoparticles for dual-targeted immunogene therapy against cancer. 2020 , 6, eaax5032	68

530	Resistance Mechanisms and Barriers to Successful Immunotherapy for Treating Glioblastoma. 2020 , 9,	32
529	V α T cell subsets, defined by PD-1 and TIM-3 expression, present varied cytokine responses in acute myeloid leukemia patients. 2020 , 80, 106122	9
528	Association of TIM-3 with BCLC Stage, Serum PD-L1 Detection, and Response to Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma. 2020 , 12,	11
527	Beyond the concept of cold and hot tumors for the development of novel predictive biomarkers and the rational design of immunotherapy combination. 2020 , 147, 1509-1518	18
526	Resistance Mechanism of PD-1/PD-L1 Blockade in the Cancer-Immunity Cycle. 2020 , 13, 83-94	16
525	Genetic and Epigenetic Biomarkers of Immune Checkpoint Blockade Response. 2020 , 9,	33
524	Significance of TIM-3 Expression in Resected Esophageal Squamous Cell Carcinoma. 2020 , 109, 1551-1557	9
523	Concurrent Injection of Unlabeled Antibodies Allows Positron Emission Tomography Imaging of Programmed Cell Death Ligand 1 Expression in an Orthotopic Pancreatic Tumor Model. 2020 , 5, 8474-8482	3
522	HPV Involvement in the Tumor Microenvironment and Immune Treatment in Head and Neck Squamous Cell Carcinomas. 2020 , 12,	18
521	The interplay between innate and adaptive immunity in cancer shapes the productivity of cancer immunosurveillance. 2020 , 108, 363-376	19
520	Acquired Resistance to Immune Checkpoint Inhibitors. 2020 , 37, 443-455	138
519	Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce. 2020 , 8,	43
518	Resistance Mechanisms Towards CD38-Directed Antibody Therapy in Multiple Myeloma. 2020 , 9,	13
517	Effectiveness of PD-1/PD-L1 inhibitors in the treatment of lung cancer: Brightness and challenge. 2020 , 63, 1499-1514	12
516	FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1, Enhances T-Cell Activation Resulting in Potent Antitumor Activity. 2020 , 26, 3333-3344	33
515	Tumor-Intrinsic or Drug-Induced Immunogenicity Dictates the Therapeutic Success of the PD1/PDL Axis Blockade. 2020 , 9,	4
514	ImmunoPET Imaging of TIM-3 in Murine Melanoma Models. 2020 , 3, 2000018	3
513	Emerging role of PTEN loss in evasion of the immune response to tumours. 2020 , 122, 1732-1743	31

512	Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition. <i>Nature Communications</i> , 2020 , 11, 1897	17.4	63
511	Identification and characterization of M6903, an antagonistic anti-TIM-3 monoclonal antibody. 2020 , 9, 1744921		12
510	Immune involvement of the contralateral hemisphere in a glioblastoma mouse model. 2020 , 8,		4
509	Biomarkers Associated with Beneficial PD-1 Checkpoint Blockade in Non-Small Cell Lung Cancer (NSCLC) Identified Using High-Plex Digital Spatial Profiling. 2020 , 26, 4360-4368		32
508	Hyperprogression Under Immune Checkpoint-Based Immunotherapy-Current Understanding, The Role of PD-1/PD-L1 Tumour-Intrinsic Signalling, Future Directions and a Potential Large Animal Model. 2020 , 12,		10
507	Evolving Role of Daratumumab: From Backbencher to Frontline Agent. 2020 , 20, 572-587		9
506	Resistance mechanisms to immune checkpoints blockade by monoclonal antibody drugs in cancer immunotherapy: Focus on myeloma. 2021 , 236, 791-805		3
505	Immune cell constitution in the tumor microenvironment predicts the outcome in diffuse large B-cell lymphoma. 2021 , 106, 718-729		25
504	Downregulation of Interferon- Receptor Expression Endows Resistance to Anti-Programmed Death Protein 1 Therapy in Colorectal Cancer. 2021 , 376, 21-28		0
503	Combination therapy with PD-1/PD-L1 blockade in non-small cell lung cancer: strategies and mechanisms. 2021 , 219, 107694		20
502	The presence of TIM-3 positive cells in WHO grade III and IV astrocytic gliomas correlates with isocitrate dehydrogenase mutation status. 2021 , 31, e12921		1
501	Targeted treatment of alcoholic liver disease based on inflammatory signalling pathways. 2021 , 222, 107752		5
500	Recent Advances in Hyperthermia Therapy-Based Synergistic Immunotherapy. 2021 , 33, e2004788		69
499	Systematic review of radiomic biomarkers for predicting immune checkpoint inhibitor treatment outcomes. 2021 , 188, 61-72		3
498	Expression of the Immune Checkpoint Regulators LAG-3 and TIM-3 in Classical Hodgkin Lymphoma. 2021 , 21, 257-266.e3		13
497	Combination therapy with anti-T-cell immunoglobulin and mucin-domain containing molecule 3 and radiation improves antitumor efficacy in murine hepatocellular carcinoma. 2021 , 36, 1357-1365		4
496	Long non-coding RNAs: Emerging regulators for chemo/immunotherapy resistance in cancer stem cells. 2021 , 500, 244-252		10
495	Anti-PD-1 antibody-mediated activation of type 17 T-cells undermines checkpoint blockade therapy. 2021 , 70, 1789-1796		3

494	The cutting-edge progress of immune-checkpoint blockade in lung cancer. 2021 , 18, 279-293	19
493	Pharmacological combination of nivolumab with dendritic cell vaccines in cancer immunotherapy: An overview. 2021 , 164, 105309	5
492	Emerging immunotherapies for metastasis. 2021 , 124, 37-48	7
491	Relationship between immune checkpoint proteins, tumour microenvironment characteristics, and prognosis in primary operable colorectal cancer. 2021 , 7, 121-134	3
490	TIM-3 pathway dysregulation and targeting in cancer. 2021 , 21, 523-534	12
489	Characterization of the tumor immune microenvironment in human papillomavirus-positive and -negative head and neck squamous cell carcinomas. 2021 , 70, 1227-1237	7
488	A balance score between immune stimulatory and suppressive microenvironments identifies mediators of tumour immunity and predicts pan-cancer survival. 2021 , 124, 760-769	2
487	Reinvigorating exhausted CD8 cytotoxic T lymphocytes in the tumor microenvironment and current strategies in cancer immunotherapy. 2021 , 41, 156-201	17
486	Immune checkpoint: The novel target for antitumor therapy. 2021 , 8, 25-37	5
485	Soluble immune checkpoints and T-cell subsets in blood as biomarkers for resistance to immunotherapy in melanoma patients. 2021 , 10, 1926762	9
484	Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors. 2021 , 27, 2773-2781	14
483	Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 Antibody. 2021 , 27, 2168-2178	22
482	Addition of anti-TIM3 or anti-TIGIT Antibodies to anti-PD1 Blockade Augments Human T cell Adoptive Cell Transfer. 2021 , 10, 1873607	4
481	Biohybrid Nanosystems for Cancer Treatment: Merging the Best of Two Worlds. 2021 , 1295, 135-162	
480	IFN- γ and CD38 in Hyperprogressive Cancer Development. 2021 , 13,	7
479	Front Line Applications and Future Directions of Immunotherapy in Small-Cell Lung Cancer. 2021 , 13,	3
478	Effect of radiotherapy on T cell and PD-1 / PD-L1 blocking therapy in tumor microenvironment. 2021 , 17, 1555-1567	7
477	A Borderless Solution Is Needed for A Borderless Complexity, Like COVID-19, the Universal Invader. 2021 , 1318, 891-910	

476	Sequential administration of anti-PD-1 and anti-Tim-3 combined with an SA-GM-CSF-anchored vaccine overcomes adaptive immune resistance to reject established bladder cancer. 2021 , 12, 2000-2009	0
475	Challenges and future prospects of nano-enabled cancer management. 2021 , 229-233	1
474	Complex Interaction Among Immune, Inflammatory, and Carcinogenic Mechanisms in the Head and Neck Squamous Cell Carcinoma. 2021 , 1335, 11-35	6
473	Immune checkpoint inhibition in myeloid malignancies: Moving beyond the PD-1/PD-L1 and CTLA-4 pathways. 2021 , 45, 100709	12
472	Peripheral CD4 T cell signatures in predicting the responses to anti-PD-1/PD-L1 monotherapy for Chinese advanced non-small cell lung cancer. 2021 , 64, 1590-1601	2
471	Fine-Tuning the Tumour Microenvironment: Current Perspectives on the Mechanisms of Tumour Immunosuppression. 2021 , 10,	5
470	NK Cells in Immunotherapy: How Important Are They?. 2021 , 65-81	
469	Discovery of acquired molecular signature on immune checkpoint inhibitors in paired tumor tissues. 2021 , 70, 1755-1769	2
468	Gold digging: Searching for gut microbiota that enhances antitumor immunity. 2021 , 236, 5495-5511	1
467	Targeting B7-H3 via chimeric antigen receptor T cells and bispecific killer cell engagers augments antitumor response of cytotoxic lymphocytes. 2021 , 14, 21	14
466	Combined inhibition of PD-1/PD-L1, Lag-3, and Tim-3 axes augments antitumor immunity in gastric cancer-T cell coculture models. 2021 , 24, 611-623	10
465	Current and Future Perspectives of PD-1/PDL-1 Blockade in Cancer Immunotherapy. 2021 , 2021, 6661406	26
464	Meeting Immunotherapy Resistance in Lung Cancer. 2021 , 16, 187-190	1
463	Functionally Competent, PD-1 CD8 Trm Cells Populate the Brain Following Local Antigen Encounter. 2020 , 11, 595707	2
462	CD39PD-1CD8 T cells mediate metastatic dormancy in breast cancer. <i>Nature Communications</i> , 2021 , 12, 769	17.4 10
461	Immune-Checkpoint Inhibitors Combinations in Metastatic NSCLC: New Options on the Horizon?. 2021 , 10, 9-26	7
460	The Many Facets of Therapy Resistance and Tumor Recurrence in Glioblastoma. 2021 , 10,	20
459	Emerging dynamics pathways of response and resistance to PD-1 and CTLA-4 blockade: tackling uncertainty by confronting complexity. 2021 , 40, 74	2

458	Clinical Significance of a Novel Tumor Progression-Associated Immune Signature in Colorectal Adenocarcinoma. 2021 , 9, 625212	1
457	Precision Medicine Approaches to Overcome Resistance to Therapy in Head and Neck Cancers. 2021 , 11, 614332	9
456	Immune classification of clear cell renal cell carcinoma. 2021 , 11, 4338	8
455	Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors. 2021 , 9,	25
454	Combination immunotherapy strategies for glioblastoma. 2021 , 151, 375-391	14
453	Identifying key questions in the ecology and evolution of cancer. 2021 , 14, 877-892	17
452	Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition. 2021 , 184, 596-614.e14	144
451	Potential therapeutic targets in the tumor microenvironment of hepatocellular carcinoma: reversing the protumor effect of tumor-associated macrophages. 2021 , 40, 73	10
450	Beyond First-Line Immunotherapy: Potential Therapeutic Strategies Based on Different Pattern Progressions: Oligo and Systemic Progression. 2021 , 13,	2
449	Adaptive Mechanisms of Tumor Therapy Resistance Driven by Tumor Microenvironment. 2021 , 9, 641469	30
448	Fighting Drug Resistance through the Targeting of Drug-Tolerant Persister Cells. 2021 , 13,	12
447	Understanding the Immune-Stroma Microenvironment in B Cell Malignancies for Effective Immunotherapy. 2021 , 11, 626818	1
446	Releasing the brakes of tumor immunity with anti-PD-L1 and pushing its accelerator with L19-IL2 cures poorly immunogenic tumors when combined with radiotherapy. 2021 , 9,	6
445	A combination of PD-1/PD-L1 inhibitors: The prospect of overcoming the weakness of tumor immunotherapy (Review). 2021 , 23,	7
444	Immunotherapy for recurrent glioblastoma: practical insights and challenging prospects. 2021 , 12, 299	5
443	In vivo CD8 T cell CRISPR screening reveals control by Flt1 in infection and cancer. 2021 , 184, 1262-1280.e22	21
442	Immune checkpoint inhibitor-associated myocarditis: manifestations and mechanisms. 2021 , 131,	19
441	Co-inhibitor expression on tumor infiltrating and splenic lymphocytes after dual checkpoint inhibition in a microsatellite stable model of colorectal cancer. 2021 , 11, 6956	0

440	Chronic Adrenergic Stress Contributes to Metabolic Dysfunction and an Exhausted Phenotype in T Cells in the Tumor Microenvironment. 2021 , 9, 651-664	8
439	Nivolumab + Ipilimumab for patients with hepatocellular carcinoma previously treated with Sorafenib. 2021 , 15, 589-598	5
438	Overcoming Resistance to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinomas. 2021 , 11, 596290	5
437	Malignant Pleural Effusions-A Window Into Local Anti-Tumor T Cell Immunity?. 2021 , 11, 672747	3
436	Development of Immunotherapy Combination Strategies in Cancer. 2021 , 11, 1368-1397	27
435	Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors. 2021 , 27, 3620-3629	18
434	Depleting Tumor Cells Expressing Immune Checkpoint Ligands-A New Approach to Combat Cancer. 2021 , 10,	0
433	Targeting STAT3 Abrogates Tim-3 Upregulation of Adaptive Resistance to PD-1 Blockade on Regulatory T Cells of Melanoma. 2021 , 12, 654749	1
432	Clinical factors associated with shorter durable response, and patterns of acquired resistance to first-line pembrolizumab monotherapy in PD-L1-positive non-small-cell lung cancer patients: a retrospective multicenter study. 2021 , 21, 346	5
431	Immunogenic cell death-inducing chemotherapeutic nanoformulations potentiate combination chemoimmunotherapy. 2021 , 202, 109465	12
430	Emerging principles of brain immunology and immune checkpoint blockade in brain metastases. 2021 , 144, 1046-1066	10
429	In Vitro Evaluation of CD276-CAR NK-92 Functionality, Migration and Invasion Potential in the Presence of Immune Inhibitory Factors of the Tumor Microenvironment. 2021 , 10,	3
428	Effect of physicochemical properties on fate of nanoparticle-based cancer immunotherapies. 2021 , 11, 886-902	8
427	Overcoming Resistance to Tumor-Targeted and Immune-Targeted Therapies. 2021 , 11, 874-899	26
426	Enhancing a Natural Killer: Modification of NK Cells for Cancer Immunotherapy. 2021 , 10,	4
425	Recent Advances and Future Prospects in Immune Checkpoint (ICI)-Based Combination Therapy for Advanced HCC. 2021 , 13,	4
424	Resistance mechanisms to checkpoint inhibitors. 2021 , 69, 47-55	4
423	Repositioning Azelnidipine as a Dual Inhibitor Targeting CD47/SIRPα and TIGIT/PVR Pathways for Cancer Immuno-Therapy. 2021 , 11,	7

422	Targeting Neuroinflammation in Brain Cancer: Uncovering Mechanisms, Pharmacological Targets, and Neuropharmaceutical Developments. 2021 , 12, 680021	5
421	Clinical Insights Into Novel Immune Checkpoint Inhibitors. 2021 , 12, 681320	22
420	Generation of TIM3 inhibitory single-domain antibodies to boost the antitumor activity of chimeric antigen receptor T cells. 2021 , 22, 542	0
419	Mechanisms of primary and acquired resistance to PD-1/PD-L1 blockade and the emerging role of gut microbiome. 2021 , 23, 2237-2252	1
418	Immunotherapy for Glioblastoma: Current Progress and Challenges. 2021 , 12, 676301	11
417	Clinical Perspectives to Overcome Acquired Resistance to Anti-Programmed Death-1 and Anti-Programmed Death Ligand-1 Therapy in Non-Small Cell Lung Cancer. 2021 , 44, 363-373	4
416	5-Aminolevulinic acid/sodium ferrous citrate enhanced the antitumor effects of programmed cell death-ligand 1 blockade by regulation of exhausted T cell metabolism in a melanoma model. 2021 , 112, 2652-2663	2
415	A four-hypoxia-genes-based prognostic signature for oral squamous cell carcinoma. 2021 , 21, 232	3
414	Emerging role of autophagy in anti-tumor immunity: Implications for the modulation of immunotherapy resistance. 2021 , 56, 100752	9
413	Epigenetic Features of HIV-Induced T-Cell Exhaustion Persist Despite Early Antiretroviral Therapy. 2021 , 12, 647688	1
412	Classification of Non-Small Cell Lung Cancer's Tumor Immune Micro-Environment and Strategies to Augment Its Response to Immune Checkpoint Blockade. 2021 , 13,	8
411	Molecular subtype identification and prognosis stratification by a metabolism-related gene expression signature in colorectal cancer. 2021 , 19, 279	4
410	Secretion of bispecific protein of anti-PD-1 fused with TGF- β trap enhances antitumor efficacy of CAR-T cell therapy. 2021 , 21, 144-157	10
409	The Tumor Microenvironment Factors That Promote Resistance to Immune Checkpoint Blockade Therapy. 2021 , 11, 641428	8
408	Resistance mechanisms to programmed cell death protein 1 and programmed death ligand 1 inhibitors. 2021 , 21, 1575-1590	2
407	Immune Aging and Immunotherapy in Cancer. 2021 , 22,	7
406	Acquired Resistance to Immune Checkpoint Blockades: The Underlying Mechanisms and Potential Strategies. 2021 , 12, 693609	4
405	Clinical and Molecular Heterogeneity in Patients with Innate Resistance to Anti-PD-1 +/- Anti-CTLA-4 Immunotherapy in Metastatic Melanoma Reveals Distinct Therapeutic Targets. 2021 , 13,	3

404	Cancer immunotherapy: it's time to better predict patients' response. 2021 , 125, 927-938	6
403	Commensal microbiota contributes to predicting the response to immune checkpoint inhibitors in non-small-cell lung cancer patients. 2021 , 112, 3005-3017	5
402	CD4 T-Cell Exhaustion: Does It Exist and What Are Its Roles in Cancer?. 2021 , 27, 5742-5752	12
401	PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy. 2021 , 4, 699	24
400	The inhibitory receptor TIM-3 limits activation of the cGAS-STING pathway in intra-tumoral dendritic cells by suppressing extracellular DNA uptake. 2021 , 54, 1154-1167.e7	18
399	SOX9 has distinct roles in the formation and progression of different non-small cell lung cancer histotypes. 2021 , 255, 16-29	0
398	Targeting dual gene delivery nanoparticles overcomes immune checkpoint blockade induced adaptive resistance and regulates tumor microenvironment for improved tumor immunotherapy. 2021 , 38, 101194	8
397	Self-assembled peptide and protein nanostructures for anti-cancer therapy: Targeted delivery, stimuli-responsive devices and immunotherapy. 2021 , 38,	36
396	Near-Complete Response to Combined Pembrolizumab and Platinum-Doublet in a Patient With STK11/KRAS Mutated Advanced Lung Adenocarcinoma. 2021 ,	1
395	Nanomedicinary evaluation of calotropis procera mediated silver nanoparticle on skin cancer cell line for microbes-front line analysis. 2021 , 1235, 130237	0
394	A novel and effective approach to generate germline-like monoclonal antibodies by integration of phage and mammalian cell display platforms. 2021 ,	1
393	Targeting Immune Modulators in Glioma While Avoiding Autoimmune Conditions. 2021 , 13,	2
392	Myeloid-Derived Suppressor Cells: Implications in the Resistance of Malignant Tumors to T Cell-Based Immunotherapy. 2021 , 9, 707198	4
391	Adenovirus Armed With TNF α and IL2 Added to aPD-1 Regimen Mediates Antitumor Efficacy in Tumors Refractory to aPD-1. 2021 , 12, 706517	3
390	Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer.	
389	Identification of a Novel Tumor Microenvironment Prognostic Signature for Advanced-Stage Serous Ovarian Cancer. 2021 , 13,	3
388	The Role of Cytokines in Predicting the Response and Adverse Events Related to Immune Checkpoint Inhibitors. 2021 , 12, 670391	8
387	Hyperprogressive Disease in Cancers Treated With Immune Checkpoint Inhibitors. 2021 , 12, 678409	4

386	Recent Advances in Glioma Therapy: Combining Vascular Normalization and Immune Checkpoint Blockade. 2021 , 13,	2
385	Immunotherapy in Glioblastoma: A Clinical Perspective. 2021 , 13,	3
384	Breast cancer resistance mechanisms: challenges to immunotherapy. 2021 , 190, 5-17	3
383	Strengthening the CAR-T cell therapeutic application using CRISPR/Cas9 technology. 2021 , 118, 3691-3705	7
382	Evolving therapeutic strategies for advanced hepatocellular carcinoma. 2021 , 22, 2495-2506	
381	The TIM3/Gal9 signaling pathway: An emerging target for cancer immunotherapy. 2021 , 510, 67-78	13
380	Immunotherapy against programmed death-1/programmed death ligand 1 in hepatocellular carcinoma: Importance of molecular variations, cellular heterogeneity, and cancer stem cells. 2021 , 13, 795-824	0
379	The Next-Generation of Combination Cancer Immunotherapy: Epigenetic Immunomodulators Transmogrify Immune Training to Enhance Immunotherapy. 2021 , 13,	1
378	LAG3 and PD1 Regulate CD8+ T Cell in Diffuse Large B-cell Lymphoma Patients. 2021 , 2021, 4468140	
377	Safety and Antitumor Activity of PD-L1 Antibody as Monotherapy or in Combination with TIM-3 Antibody in Patients with Microsatellite Instability-High/Mismatch Repair-Deficient Tumors. 2021 , 27, 6393-6404	7
376	Neuroinflammation in Autoimmune Disease and Primary Brain Tumors: The Quest for Striking the Right Balance. 2021 , 15, 716947	1
375	Structure and functions of T-cell immunoglobulin-domain and mucin- domain protein 3 in cancer. 2021 ,	0
374	Immune Checkpoint Inhibitors in Colorectal Cancer: Challenges and Future Prospects. 2021 , 9,	7
373	Role of Ezrin/Radixin/Moesin in the Surface Localization of Programmed Cell Death Ligand-1 in Human Colon Adenocarcinoma LS180 Cells. 2021 , 14,	2
372	Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760). 2021 , 9,	5
371	Strategies to Overcome Failures in T-Cell Immunotherapies by Targeting PI3K- and - γ 2021 , 12, 718621	3
370	Quality Is King: Fundamental Insights into Tumor Antigenicity from Virus-Associated Merkel Cell Carcinoma. 2021 , 141, 1897-1905	2
369	Critical View of Novel Treatment Strategies for Glioblastoma: Failure and Success of Resistance Mechanisms by Glioblastoma Cells. 2021 , 9, 695325	6

368	mTOR Inhibition Increases Transcription Factor E3 (TFE3) Activity and Modulates Programmed Death-Ligand 1 (PD-L1) Expression in Translocation Renal Cell Carcinoma. 2021 , 191, 1999-2008	0
367	Dynamic alterations of circulating T lymphocytes and the clinical response in patients with head and neck squamous cell carcinoma treated with nivolumab. 2021 , 1	1
366	Tumor microenvironment is not an 'innocent bystander' in the resistance to treatment of head and neck cancers (Review). 2021 , 22, 1128	1
365	Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer. 2021 , 32, 1597-1607	4
364	Profiling the inhibitory receptors LAG-3, TIM-3, and TIGIT in renal cell carcinoma reveals malignancy. <i>Nature Communications</i> , 2021 , 12, 5547	17.4 5
363	Expression, prognostic significance and therapeutic implications of PD-L1 in gliomas. 2021 ,	1
362	T cell exhaustion drives osteosarcoma pathogenesis. 2021 , 9, 1447	2
361	Resistance to immunotherapy in human malignancies: Mechanisms, research progresses, challenges, and opportunities. 2021 ,	3
360	Ezrin Modulates the Cell Surface Expression of Programmed Cell Death Ligand-1 in Human Cervical Adenocarcinoma Cells. 2021 , 26,	2
359	Clinical Efficacy and Future Prospects of Immunotherapy in Lung Cancer. 2021 , 11,	2
358	Tumor associated antigen specific T cells with nivolumab are safe and persist in vivo in rel/ref Hodgkin Lymphoma. 2021 ,	1
357	Targeting Tim-3 in Cancer With Resistance to PD-1/PD-L1 Blockade. 2021 , 11, 731175	6
356	Contribution of Ezrin on the Cell Surface Plasma Membrane Localization of Programmed Cell Death Ligand-1 in Human Choriocarcinoma JEG-3 Cells. 2021 , 14,	1
355	Advanced nanomedicine approaches applied for treatment of skin carcinoma. 2021 , 337, 589-611	17
354	Nanobodies Enhancing Cancer Visualization, Diagnosis and Therapeutics. 2021 , 22,	1
353	Combination strategies to maximize the benefits of cancer immunotherapy. 2021 , 14, 156	19
352	Immune checkpoints and immunotherapy in non-small cell lung cancer: Novel study progression, challenges and solutions. 2021 , 22, 787	2
351	Fragment-Based Discovery of Small Molecules Bound to T-Cell Immunoglobulin and Mucin Domain-Containing Molecule 3 (TIM-3). 2021 , 64, 14757-14772	1

350	The abnormal expression of Tim-3 is involved in the regulation of myeloid-derived suppressor cells and its correlation with preeclampsia. 2021 , 114, 108-114	0
349	Immunotherapy for Head and Neck Cancer. 2021 , 35, 1021-1037	3
348	Targeted knockdown of Tim3 by short hairpin RNAs improves the function of anti-mesothelin CAR T cells. 2021 , 139, 1-9	1
347	The effect of Curcumin on multi-level immune checkpoint blockade and T cell dysfunction in head and neck cancer. 2021 , 92, 153758	2
346	Guiding immunotherapy combinations: Who gets what?. 2021 , 178, 113962	1
345	Local immunotherapy of cancer and metastasis. 2022 , 483-528	
344	Intrinsic and acquired cancer immunotherapy resistance. 2022 , 463-497	
343	Immune checkpoint blockade therapy in high-grade glioma. 2022 , 91-108	
342	Immune classification of osteosarcoma. 2021 , 18, 1879-1897	8
341	An experimental model of anti-PD-1 resistance exhibits activation of TGF β and Notch pathways and is sensitive to local mRNA immunotherapy. 2021 , 10, 1881268	6
340	Converged Rab37/IL-6 trafficking and STAT3/PD-1 transcription axes elicit an immunosuppressive lung tumor microenvironment. 2021 , 11, 7029-7044	5
339	Tumor microenvironment: an evil nexus promoting aggressive head and neck squamous cell carcinoma and avenue for targeted therapy. 2021 , 6, 12	18
338	Update of early phase clinical trials in cancer immunotherapy. 2021 , 54, 70-88	4
337	Immune Resistance in Lung Adenocarcinoma. 2021 , 13,	19
336	Immunotherapy in Colorectal Cancer: Current and Future Strategies. 2021 , 5, 11-24	18
335	Sono/Photodynamic Nanomedicine-Elicited Cancer Immunotherapy. 2021 , 31, 2008061	22
334	Hyperprogression: A novel response pattern under immunotherapy. 2020 , 10, e167	11
333	Mechanisms of NK cell dysfunction in the tumor microenvironment and current clinical approaches to harness NK cell potential for immunotherapy. 2021 , 109, 1071-1088	10

332	Status of Immune Oncology: Challenges and Opportunities. 2020 , 2055, 3-21	5
331	Immunological Targets for Immunotherapy: Inhibitory T Cell Receptors. 2020 , 2055, 23-60	5
330	Immune Therapies. 2019 , 239-253	1
329	Advances and Challenges of CAR T Cells in Clinical Trials. 2020 , 214, 93-128	7
328	Chimeric Antigen Receptors for the Tumour Microenvironment. 2020 , 1263, 117-143	7
327	Therapeutic Development of Immune Checkpoint Inhibitors. 2020 , 1248, 619-649	9
326	Mechanisms of Resistance to Checkpoint Blockade Therapy. 2020 , 1248, 83-117	15
325	Inhibition of the adenosine A2a receptor modulates expression of T cell coinhibitory receptors and improves effector function for enhanced checkpoint blockade and ACT in murine cancer models. 2018 , 67, 1271-1284	76
324	Early transient suppression of immune checkpoint proteins T-cell immunoglobulin mucin-3 and programmed cell death-1 in peripheral blood lymphocytes after blastocyst transfer is associated with successful implantation. 2020 , 114, 426-435	3
323	Cancer immune resistance: can theories converge?. 2017 , 1, 411-419	9
322	TAM kinase inhibition and immune checkpoint blockade- a winning combination in cancer treatment?. 2021 , 25, 141-151	6
321	ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma. 2020 , 58, 1-24	16
320	Immunophenotype of Vestibular Schwannomas. 2020 , 41, e1290-e1296	3
319	Clinical Significance of Program Death Ligand-1 and Indoleamine-2,3-Dioxygenase Expression in Colorectal Carcinoma. 2021 , 29, 201-208	3
318	Combining radiomics and mathematical modeling to elucidate mechanisms of resistance to immune checkpoint blockade in non-small cell lung cancer.	3
317	Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement. 2018 , 3,	68
316	Multiparametric profiling of non-small-cell lung cancers reveals distinct immunophenotypes. 2016 , 1, e89014	79
315	Emerging strategies for combination checkpoint modulators in cancer immunotherapy. 2018 , 128, 3209-3218	107

314	Immune overdrive signature in colorectal tumor subset predicts poor clinical outcome. 2019 , 129, 4464-4476	35
313	Evolution of Lung Cancer in the Context of Immunotherapy. 2020 , 14, 1179554920979697	1
312	ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma. 2020 , 55,	57
311	Immune regulation by Tim-3. 2018 , 7, 316	49
310	Establishment of a novel risk score model by comprehensively analyzing the immunogen database of bladder cancer to indicate clinical significance and predict prognosis. 2020 , 12, 11967-11989	6
309	Breaking the crosstalk of the cellular tumorigenic network: Hypothesis for addressing resistances to targeted therapies in advanced NSCLC. 2017 , 8, 43555-43570	8
308	Clinical and molecular features of innate and acquired resistance to anti-PD-1/PD-L1 therapy in lung cancer. 2018 , 9, 4375-4384	16
307	Interleukin 8 activity influences the efficacy of adenoviral oncolytic immunotherapy in cancer patients. 2018 , 9, 6320-6335	9
306	Immunoclassification characterized by CD8 and PD-L1 expression is associated with the clinical outcome of gastric cancer patients. 2018 , 9, 12164-12173	12
305	PD-L1 expression in medulloblastoma: an evaluation by subgroup. 2018 , 9, 19177-19191	24
304	T-cell exhaustion in glioblastoma. 2018 , 9, 35287-35288	14
303	Co-inhibitory T cell receptor KLRG1: human cancer expression and efficacy of neutralization in murine cancer models. 2019 , 10, 1399-1406	17
302	Hyperprogression and impact of tumor growth kinetics after PD1/PDL1 inhibition in head and neck squamous cell carcinoma. 2020 , 11, 1618-1628	6
301	Resistance mechanisms in melanoma to immuneoncologic therapy with checkpoint inhibitors.. 2019 , 2, 744-761	1
300	Biomarkers of resistance to immune checkpoint inhibitors in non-small-cell lung cancer: myth or reality?. 2020 , 3, 276-286	2
299	Emerging uses of biomarkers in lung cancer management: molecular mechanisms of resistance. 2017 , 5, 377	11
298	Predictors of response and resistance to checkpoint inhibitors in solid tumors. 2017 , 5, 468	7
297	The PD-1/PD-L1 pathway in advanced prostate cancer-have we milked this cow?. 2019 , 7, 346	5

296	T cell immunoglobulin and mucin-domain containing-3 in non-small cell lung cancer. 2019 , 8, 895-906	18
295	Tim-3 promotes cell aggressiveness and paclitaxel resistance through NF- κ B/STAT3 signalling pathway in breast cancer cells. 2020 , 32, 564-579	6
294	Immune Checkpoint Inhibitors: Basics and Challenges. 2019 , 26, 3009-3025	102
293	Melanoma: Prognostic Factors and Factors Predictive of Response to Therapy. 2020 , 27, 2792-2813	4
292	Genitourinary Tumors: Update on Molecular Biomarkers for Diagnosis, Prognosis and Prediction of Response to Therapy. 2019 , 20, 305-312	7
291	Upregulation of Galectin-9 and PD-L1 Immune Checkpoints Molecules in Patients with Chronic Lymphocytic Leukemia. 2017 , 18, 2269-2274	20
290	Combinations using checkpoint blockade to overcome resistance. 2020 , 14, 1148	6
289	Combined Anti-Cancer Strategies Based on Anti-Checkpoint Inhibitor Antibodies. 2020 , 9,	6
288	The TLR4/ERK/PD-L1 axis may contribute to NSCLC initiation. 2020 , 57, 456-465	4
287	Enhanced Immunotherapeutic Efficacy of Anti-PD-L1 Antibody in Combination with an EP4 Antagonist. 2020 , 4, 837-850	7
286	Tumour Regression via Integrative Regulation of Neurological, Inflammatory, and Hypoxic Tumour Microenvironment. 2020 , 28, 119-130	5
285	Evaluating Antitumor Activity of Kiatomab by Targeting Cancer Stem Cell-Specific KIAA1114 Antigen in Mice. 2019 , 19, e43	2
284	Cancer immunotherapy by targeting immune checkpoint receptors. 2018 , 8, 1-11	4
283	Increased Tim-3 expression on TILs during treatment with the Anchored GM-CSF vaccine and anti-PD-1 antibodies is inversely correlated with response in prostate cancer. 2020 , 11, 648-656	19
282	T-ALL leukemia stem cell 'stemness' is epigenetically controlled by the master regulator SPI1. 2018 , 7,	20
281	Selective targeting of CD38 hydrolase and cyclase activity as an approach to immunostimulation.. 2021 , 11, 33260-33270	0
280	PTX3 Mediates the Infiltration, Migration, and M2-Polarization of Macrophages in Glioblastoma by Large-Scale Single Cell Sequencing Analysis and in vitro Experiments.	
279	Nature vs. Nurture: The Two Opposing Behaviors of Cytotoxic T Lymphocytes in the Tumor Microenvironment. 2021 , 22,	1

278	T Cell-Signaling-Responsive Conjugate of Antibody with siRNA to Overcome Acquired Resistance to anti-PD-1 Immunotherapy. 2100161	3
277	Review of the recent clinical trials for PD-1/PD-L1 based lung cancer immunotherapy. 2021 , 21, 1355-1370	1
276	The Balance between Differentiation and Terminal Differentiation Maintains Oral Epithelial Homeostasis. 2021 , 13,	0
275	Overcoming Resistance to Immunotherapy in Advanced Cutaneous Squamous Cell Carcinoma. 2021 , 13,	1
274	PD-1 and TIGIT downregulation distinctly affect the effector and early memory phenotypes of CD19-targeting CAR T cells. 2021 ,	4
273	Adaptive resistance in tumors to anti-PD-1 therapy through re-immunosuppression by upregulation of GPNMB expression. 2021 , 101, 108199	1
272	Tim-3 co-stimulation promotes short-term effector T cells, restricts memory precursors and is dispensable for T cell exhaustion.	1
271	Current Advances in Immuno-oncology for Head and Neck Cancer. 2018 , 9, 78-86	
270	ULTRASOUND TUMOR ABLATION: IMMUNE EFFECTS AND PERSPECTIVES OF INTEGRATION IN THE MODERN TREATMENT OF ADVANCED CANCER. 2018 , 8, 31-42	
269	Gut Microbiome and the Response to Immunotherapy in Cancer. 2018 , 6, e84	2
268	Mechanisms of resistance to anti-Pd-1 therapy in metastatic cutaneous melanoma. 2018 , 17, 34-46	2
267	Biological Events and Barriers to Effective Delivery of Cancer Therapeutics. 2019 , 13-31	
266	Novel Methods to Overcome Acquired Resistance to Immunotherapy. 2019 , 97-129	
265	Checkpoint Inhibitors in the Treatment of Metastatic Melanoma. 2019 , 1-24	
264	Mechanism of resistance to immune checkpoint inhibitors.. 2019 , 2, 178-188	2
263	Landscape of tumor-infiltrating immune cells in human immunogenic cancers: B cells are inversely associated with CD8T cells, but positively correlated with Treg cells.	
262	Overcoming Immunological Resistance Enhances the Efficacy of a Novel anti-tMUC1 CAR T Cell Treatment Against Pancreatic Ductal Adenocarcinoma.	1
261	Novel syngeneic animal model of tobacco-associated oral cancer reveals the activity of in situ anti-CTLA-4.	

260	Functional Genome Profiling to Understand Cancer Immune Responsiveness. 2020 , 2055, 231-244	
259	Immunotherapy in Oral Cancer: A Fourth Dimension of Cancer Treatment. 2020 , 129-154	0
258	Checkpoint Inhibitors in the Treatment of Metastatic Melanoma. 2020 , 1141-1164	
257	Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase 2 Trial.	
256	Pure Biologics IFrom a Bootstrapped Boutique CRO to an Integrated Drug Discovery Public Company. 2020 , 7, 48-63	
255	Fighting Cancer Resistance: An Overview. 2021 , 2174, 3-12	1
254	Molecular Analysis of Elements of Melanoma Insensitivity to TCR-Engineered Adoptive Cell Therapy. 2021 , 22,	1
253	TIM3 cells in gastric cancer: clinical correlates and association with immune context. 2021 ,	0
252	The Biology of Immune-Active Cancers and Their Regulatory Mechanisms. 2020 , 180, 149-172	0
251	T lymphocytes related biomarkers for predicting immunotherapy efficacy in non-small cell lung cancer. 2021 , 21, 89	3
250	Diagnostic, prognostic, predictive and therapeutic molecular biomarkers in CRC: Understanding the present and foreseeing the future. 2022 , 207-230	
249	Current advances in kidney cancer immunotherapy. 2020 , 15, 30-38	2
248	Perspectives on the Role of T Cell Negative Immune Checkpoint Receptors in Health and Disease. 2020 , 297-318	
247	Hodgkin Lymphoma and PD-1 Blockade. 2020 , 395-409	
246	PD1/PDL1 expression is associated with increased TIM3 expression and tumor-infiltrating T lymphocytes in fibroblastic tumors. 2021 , 1	
245	Current Perspectives on the Immunosuppressive Niche and Role of Fibrosis in Hepatocellular Carcinoma and the Development of Antitumor Immunity. 2021 , 221554211056853	1
244	Mechanisms of resistance to immune checkpoint inhibitors. 2020 , 28, 857-864	
243	Heterogeneous responses in hepatocellular carcinoma: the achilles heel of immune checkpoint inhibitors. 2020 , 10, 1085-1102	2

242	Is There a Role for Immunotherapy in Central Nervous System Cancers?. 2022 , 36, 237-252	0
241	Resistance to Targeted Agents Used to Treat Paediatric ALK-Positive ALCL. 2021 , 13,	0
240	Various Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges. 2021 , 11, 771335	0
239	Directing the Future Breakthroughs in Immunotherapy: The Importance of a Holistic Approach to the Tumour Microenvironment. 2021 , 13,	0
238	TIGIT/CD155 axis mediates resistance to immunotherapy in patients with melanoma with the inflamed tumor microenvironment. 2021 , 9,	2
237	Anticancer Natural Products Targeting Immune Checkpoint Protein Network. 2021 ,	0
236	Immunotherapy in Breast Cancer: When, How, and What Challenges?. 2021 , 9,	7
235	A deficient MIF-CD74 signaling pathway may play an important role in immunotherapy-induced hyper-progressive disease. 2021 , 1	2
234	Pushing Past the Blockade: Advancements in T Cell-Based Cancer Immunotherapies. 2021 , 12, 777073	0
233	Research progress of tumor targeted drug delivery based on PD-1/PD-L1.. 2022 , 616, 121527	2
232	Current progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma.. 2022 ,	3
231	Breast Cancer Tumor Microenvironment and Molecular Aberrations Hijack Tumoricidal Immunity.. 2022 , 14,	1
230	Acquired resistance for immune checkpoint inhibitors in cancer immunotherapy: challenges and prospects.. 2022 , 14,	0
229	Enhanced Chimeric Antigen Receptor T Cell Therapy through Co-Application of Synergistic Combination Partners.. 2022 , 10,	0
228	Immune checkpoint inhibitors in HCC: cellular, molecular and systemic data.. 2022 ,	2
227	Nanozyme-Based Enhanced Cancer Immunotherapy.. 2022 , 1	4
226	Immune escape mechanism behind resistance to anti-PD-1 therapy in gastrointestinal tract metastasis in malignant melanoma patients with multiple metastases.. 2022 , 1	0
225	Case Report: Sarcoid-Like Reactions and Tertiary Lymphoid Structures Following Dual Checkpoint Inhibition in a Patient with Early-Stage Lung Adenocarcinoma.. 2022 , 13, 794217	0

224	Cancer cell-expressed BTNL2 facilitates tumour immune escape via engagement with IL-17A-producing T cells.. <i>Nature Communications</i> , 2022 , 13, 231	17.4	2
223	Immunotherapy for glioblastoma: the promise of combination strategies.. 2022 , 41, 35		12
222	Identification of a unique tumor cell subset employing myeloid transcriptional circuits to create an immunomodulatory microenvironment in glioblastoma.. 2022 , 11, 2030020		0
221	Self-blockade of PD-L1 with bacteria-derived outer-membrane vesicle for enhanced cancer immunotherapy. 2021 , e2106307		5
220	Gastroenteropancreatic Neuroendocrine Neoplasms (GEP NENs) : The Role of Checkpoint Inhibitors.. 2022 ,		
219	XIST/miR-34a-5p/PDL1 axis regulated the development of lung cancer cells and the immune function of CD8 T cells.. 2022 , 1-10		1
218	Presence of Tim3 and PD-1 CD8 T cells identifies microsatellite stable colorectal carcinomas with immune exhaustion and distinct clinicopathological features.. 2022 ,		0
217	Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand?. 2022 ,		1
216	Highly efficient PD-1-targeted CRISPR-Cas9 for tumor-infiltrating lymphocyte-based adoptive T cell therapy.. 2022 , 24, 417-428		2
215	Red Blood Cell-Mimic Nanocatalyst Triggering Radical Storm to Augment Cancer Immunotherapy.. 2022 , 14, 57		4
214	Intermittent administration of tacrolimus enhances anti-tumor immunity in melanoma-bearing mice.. 2022 ,		
213	LAG-3 is a promising inhibitory immune checkpoint for antitumor immunotherapy.. 2022 , 1-8		0
212	Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer.. 2022 ,		23
211	Serial changes in two immune checkpoint receptors and ligands, Tim-3/Gal-9 and PD-1/PD-L1 in peripheral blood prior to miscarriage: comparison with pregnancies resulting in a live birth.. 2022 ,		0
210	Loss of sensitizes immune checkpoint blockade in non-small cell lung cancer.. 2022 , 8, eabi9533		2
209	Strategies targeting tumor immune and stromal microenvironment and their clinical relevance.. 2022 , 183, 114137		7
208	New Strategies and Combinations to Improve Outcomes in Immunotherapy in Metastatic Non-Small-Cell Lung Cancer.. 2021 , 29, 38-55		0
207	Transcriptomics and Immune Response in Human Cancer. 2022 , 299-315		

206	Targeting Angiogenesis in Squamous Cell Carcinoma of the Head and Neck: Opportunities in the Immunotherapy Era.. 2022 , 14,	0
205	Emerging CAR T Cell Strategies for the Treatment of AML.. 2022 , 14,	0
204	Update on lymphocyte-activation gene 3 (LAG-3) in cancers: from biological properties to clinical applications.. 2022 ,	0
203	Emerging new cell therapies/immune therapies in B-cell non-Hodgkin's lymphoma.. 2021 , 100825	0
202	Insufficiency of compound immune checkpoint blockade to overcome engineered T cell exhaustion in pancreatic cancer.. 2022 , 10,	0
201	Dacarbazine-Loaded Targeted Polymeric Nanoparticles for Enhancing Malignant Melanoma Therapy.. 2022 , 10, 847901	1
200	A strategy for the efficient construction of anti-PD1-based bispecific antibodies with desired IgG-like properties.. 2022 , 14, 2044435	0
199	Key Players of the Immunosuppressive Tumor Microenvironment and Emerging Therapeutic Strategies.. 2022 , 10, 830208	1
198	Identification of the Tumor Immune Microenvironment and Therapeutic Biomarkers by a Novel Molecular Subtype Based on Aging-Related Genes in Hepatocellular Carcinoma.. 2022 , 9, 836080	1
197	The Current State of Treatment and Future Directions in Cutaneous Malignant Melanoma.. 2022 , 10,	4
196	Current Developments and Challenges of mRNA Vaccines.. 2022 ,	3
195	Emerging photodynamic nanotherapeutics for inducing immunogenic cell death and potentiating cancer immunotherapy.. 2022 , 282, 121433	12
194	Current Understanding and Future Perspectives on Hyperprogressive Disease Highlight the Tumor Microenvironment.. 2022 ,	
193	Histone Deacetylase (HDAC) Inhibitors: A Promising Weapon to Tackle Therapy Resistance in Melanoma.. 2022 , 23,	2
192	Lung Adenocarcinoma Tumor Origin: A Guide for Personalized Medicine.. 2022 , 14,	3
191	Inhibitory Immune Checkpoint Receptors and Ligands as Prognostic Biomarkers in COVID-19 Patients.. 2022 , 13, 870283	1
190	Hyperprogressive Disease in Malignant Carcinoma With Immune Checkpoint Inhibitor Use: A Review.. 2022 , 9, 810472	0
189	Future Prospects of Immunotherapy in Non-Small-Cell Lung Cancer Patients: Is There Hope in Other Immune Checkpoints Targeting Molecules?. 2022 , 23,	1

188	Delayed dynamics of migratory response to CTLA-4 blockade reveals a mechanistic view on potential T cells reinvigoration following immune checkpoint blockade.	
187	Treatment of Recurrent and Metastatic HPV-Associated Squamous Cell Carcinoma. 1	
186	Physical activity improves outcomes of combined lenvatinib plus anti-PD-1 therapy in unresectable hepatocellular carcinoma: a retrospective study and mouse model.. 2022 , 11, 20	
185	Networks of CD8 T Cell Response Activation in Melanoma and Vitiligo.. 2022 , 13, 866703	0
184	Targeting the HVEM protein using a fragment of glycoprotein D to inhibit formation of the BTLA/HVEM complex.. 2022 , 122, 105748	0
183	Systemic levels of the soluble co-inhibitory immune checkpoints, CTLA-4, LAG-3, PD-1/PD-L1 and TIM-3 are markedly increased in basal cell carcinoma.. 2022 , 19, 101384	1
182	Cooperation between chemotherapy and immune checkpoint blockade to enhance anti-tumour T cell immunity in oesophageal adenocarcinoma.. 2022 , 20, 101406	
181	Landscape and Clinical Significance of Immune Checkpoint in Cutaneous Melanoma.. 2021 , 12, 756282	0
180	What Happens to the Immune Microenvironment After PD-1 Inhibitor Therapy?. 2021 , 12, 773168	1
179	Prognostic Value of Neoantigen Load in Immune Checkpoint Inhibitor Therapy for Cancer.. 2021 , 12, 689076	5
178	Dawning precision treatment for gastric cancer: The latest biomarkers.. 2021 , 9, 228-230	1
177	Immunotherapy Resistance in Glioblastoma.. 2021 , 12, 750675	1
176	Case Report: Tumor Microenvironment Characteristics in a Patient With HER2 Mutant Lung Squamous Cell Carcinoma Harboring High PD-L1 Expression Who Presented Hyperprogressive Disease.. 2021 , 11, 760703	3
175	Quantitative MHC class-I/-II expression levels in CDK12 mutated prostate cancer patients reveal intratumorally T cell adaptive immune response in tumors.	
174	The Landscape of Immunotherapy Resistance in NSCLC.. 2022 , 12, 817548	2
173	TNF- β -Secreting Lung Tumor-Infiltrated Monocytes Play a Pivotal Role During Anti-PD-L1 Immunotherapy.. 2022 , 13, 811867	0
172	Acquired resistance to anti-PD1 therapy in patients with NSCLC reveals changes in T cell phenotypes and MET amplification.	
171	Tumor-infiltrating lymphocytes for adoptive cell therapy: recent advances, challenges, and future directions.. 2022 ,	2

170 Hyperprogression, a challenge of PD-1/PD-L1 inhibitors treatments: potential mechanisms and coping strategies.. **2022**, 150, 112949

1

169 Data_Sheet_1.docx. **2018**,

168 Image_1.PDF. **2018**,

167 Image_2.PDF. **2018**,

166 Image_3.PDF. **2018**,

165 Image_4.PDF. **2018**,

164 Image_5.PDF. **2018**,

163 Image_6.PDF. **2018**,

162 Image_7.PDF. **2018**,

161 Image_8.PDF. **2018**,

160 Data_Sheet_1.docx. **2019**,

159 Table_1.docx. **2019**,

158 Data_Sheet_1.pdf. **2019**,

157 DataSheet_1.docx. **2020**,

156 Data_Sheet_1.docx. **2018**,

155 Image_1.JPEG. **2019**,

154 Image_2.JPEG. **2019**,

153 Table_1.docx. **2020**,

152 Data_Sheet_1.pdf. **2019,**

151 Table_1.XLSX. **2019,**

150 Table_2.xlsx. **2019,**

149 Direct and indirect regulation of the tumor immune microenvironment by VEGF.. **2022,**

0

148 An Immunity-Associated lncRNA Signature for Predicting Prognosis in Gastric Adenocarcinoma.. **2022, 2022, 3035073**

147 Glioblastoma: Pitfalls and Opportunities of Immunotherapeutic Combinations.. **2022, 15, 437-468**

1

146 Resistance Mechanisms to Anti-PD Cancer Immunotherapy.. **2022, 40, 45-74**

3

145 Engineered nanomedicines block the PD-1/PD-L1 axis for potentiated cancer immunotherapy.. **2022,**

1

144 Functionalized Lineage Tracing Can Enable the Development of Homogenization-Based Therapeutic Strategies in Cancer. **2022, 13,**

0

143 CD73/Adenosine Pathway Involvement in the Interaction of Non-Small Cell Lung Cancer Stem Cells and Bone Cells in the Pre-Metastatic Niche.. **2022, 23,**

0

142 Small Molecule Agents Targeting PD-1 Checkpoint Pathway for Cancer Immunotherapy: Mechanisms of Action and Other Considerations for Their Advanced Development.. **2022, 13, 752065**

2

141 The multi-molecular mechanisms of tumor-targeted drug resistance in precision medicine. **2022, 150, 113064**

1

140 Immuno-onco-metabolism and Therapeutic Resistance. **2022, 45-89**

3

139 An optimal portfolio of photothermal combined immunotherapy. **2022, 100898**

2

138 Cancer Immunoediting in the Era of Immuno-oncology.. **2022,**

0

137 Dynamic-Responsive Virus-Mimetic Nanocapsules Facilitate Protein Drug Penetration and Extracellular-Specific Unpacking for Antitumor Treatment.

1

136 Synthetic and biodegradable molybdenum (IV) diselenide triggers the cascade photo- and immunotherapy of tumor. 2200524

135 Galectin Family Members: Emerging Novel Targets for Lymphoma Therapy?. **2022, 12,**

0

134	Molecular and Immune Profiling of Syngeneic Mouse Models Predict Response to Immune Checkpoint Inhibitors in Gastric Cancer.	
133	Challenges in glioblastoma immunotherapy: mechanisms of resistance and therapeutic approaches to overcome them.	0
132	Nanotechnology and Immunomodulators in Cancer. 2022 , 125-186	0
131	Novel antigens for targeted radioimmunotherapy in hepatocellular carcinoma.	1
130	Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities.	9
129	Hyperprogression on anti-PD-1 treatment. Is subsequent therapy feasible? A case report and review of the literature.	
128	Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma. 13,	1
127	Modelling the tumor immune microenvironment for precision immunotherapy. 2022 , 11,	1
126	The Role of Immune Checkpoints in Cancer Progression.	
125	Tumor immunotherapy: Mechanisms and clinical applications. 2022 , 1,	
124	CHI3L1 Enhances Melanoma Lung Metastasis via Regulation of T cell Co-stimulators and CTLA-4/B7 Axis.	
123	Primary and Acquired Resistance against Immune Check Inhibitors in Non-Small Cell Lung Cancer. 2022 , 14, 3294	
122	Dynamics of Melanoma-Associated Epitope-Specific CD8+ T Cells in the Blood Correlate With Clinical Outcome Under PD-1 Blockade. 13,	
121	Mechanisms of resistance to immune checkpoint inhibitors.	0
120	Prevalence and prognostic significance of PD-L1, TIM-3 and B7-H3 expression in endometrial serous carcinoma.	0
119	Exploring immunotherapy in colorectal cancer. 2022 , 15,	5
118	The Multi-Kinase Inhibitor Lucitanib Enhances the Antitumor Activity of Coinhibitory and Costimulatory Immune Pathway Modulators in Syngeneic Models. Publish Ahead of Print,	0
117	In Vivo Syngeneic Tumor Models with Acquired Resistance to AntiPD-1/PD-L1 Therapies. OF1-OF15	1

116	Immune Checkpoint Inhibitors in Cancer Therapy How to Overcome Drug Resistance?. 2022 , 14, 3575	2
115	Addressing CPI resistance in NSCLC: targeting TAM receptors to modulate the tumor microenvironment and future prospects. 2022 , 10, e004863	1
114	Enhanced Inhibitory Effect of DC-CIK Cells on Lung Adenocarcinoma via Anti-Tim-3 Antibody and Antiprogrammed Cell Death-1 Antibody and Possible Mechanism. 2022 , 2022, 1-11	
113	PTX3 mediates the infiltration, migration, and inflammation-resolving-polarization of macrophages in glioblastoma.	1
112	Enhanced development of functional human NK cells in NOD- scid-IL2rg null mice expressing human IL15. 2022 , 36,	2
111	Modeling Resistance to Immune Checkpoint Blockade. 2022 , 107-149	
110	Targeting PD-1/PD-L1 in cancer immunotherapy: an effective strategy for treatment of triple-negative breast cancer (TNBC) patients. 2022 ,	0
109	Emerging roles of ferroptosis in glioma. 12,	0
108	Inhibition of melanoma cell-intrinsic Tim-3 stimulates MAPK-dependent tumorigenesis.	2
107	The Features of Checkpoint Receptor Ligand Interaction in Cancer and the Therapeutic Effectiveness of Their Inhibition. 2022 , 10, 2081	0
106	PD-1 and LAG-3 expression in EBV-associated pediatric Hodgkin lymphoma has influence on survival. 12,	
105	On-demand integrated nano-engager converting cold tumors to hot via increased DNA damage and dual immune checkpoint inhibition. 2022 ,	0
104	The immunosuppressive tumor microenvironment in hepatocellular carcinoma-current situation and outlook. 2022 , 151, 218-230	1
103	High-Dose Radiation Therapy and Immunotherapy in a Novel Intrarenal Syngeneic Mouse Model of Neuroblastoma.	0
102	Checkpoint Inhibitors in Non-small Cell Lung Cancer: Potentials and Challenges. 2022 ,	0
101	Editorial: Mechanisms of resistance to the targeted therapy and immunotherapy in cutaneous melanoma. 12,	0
100	Paving the Way to Solid Tumors: Challenges and Strategies for Adoptively Transferred Transgenic T Cells in the Tumor Microenvironment. 2022 , 14, 4192	0
99	Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response. 2022 , 7,	5

98	Unveiling the tumor immune microenvironment of organ-specific melanoma metastatic sites. 2022 , 10, e004884	1
97	Current Landscape of Therapeutic Resistance in Lung Cancer and Promising Strategies to Overcome Resistance. 2022 , 14, 4562	1
96	Hyperprogression under treatment with immune-checkpoint inhibitors in patients with gastrointestinal cancer: A natural process of advanced tumor progression?. 2022 , 13, 729-737	0
95	Development of Inhibitors Targeting the V-Domain Ig Suppressor of T Cell Activation Signal Pathway. 2022 , 65, 11900-11912	0
94	The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers. 13,	5
93	Mechanisms of tumor resistance to immune checkpoint blockade and combination strategies to overcome resistance. 13,	1
92	Mechanisms of Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Patients with Hepatocellular Carcinoma. 2022 , 14, 4616	0
91	Therapeutic Advances in Immunotherapies for Hematological Malignancies. 2022 , 23, 11526	0
90	Nanocarriers for cancer nano-immunotherapy.	2
89	Emerging immune checkpoint inhibitors for the treatment of non-small cell lung cancer. 1-12	0
88	Characterizing the immune checkpoint marker profiles of cutaneous squamous cell carcinomas in patients with hidradenitis suppurativa.	0
87	The Complement System: A Potential Therapeutic Target in Liver Cancer. 2022 , 12, 1532	0
86	Advances in sex disparities for cancer immunotherapy: unveiling the dilemma of Yin and Yang. 2022 , 13,	0
85	Mechanisms of primary and acquired resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer: a multiplex immunohistochemistry-based single-cell analysis. 2022 ,	0
84	Neuronal CaMKK2 promotes immunosuppression and checkpoint blockade resistance in glioblastoma. 2022 , 13,	0
83	Machine learning and bioinformatics-based insights into the potential targets of saponins in Paris polyphylla smith against non-small cell lung cancer. 13,	0
82	Clinical cancer immunotherapy: Current progress and prospects. 13,	2
81	Immune-Checkpoint Inhibitors (ICIs) in Metastatic Colorectal Cancer (mCRC) Patients beyond Microsatellite Instability. 2022 , 14, 4974	2

- 80 Advances in immunotherapy for glioblastoma multiforme. 13, ○
- 79 Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma. OF1-OF13 ○
- 78 Deciphering molecular and cellular ex vivo responses to bispecific antibodies PD1-TIM3 and PD1-LAG3 in human tumors. **2022**, 10, e005548 ○
- 77 The role of immune profile in predicting outcomes in cancer patients treated with immunotherapy. 13, 1
- 76 Cancer stem cells in immunoregulation and bypassing anti-checkpoint therapy. **2022**, 156, 113906 ○
- 75 VISTA immune regulatory effects in bypassing cancer immunotherapy: Updated. **2022**, 310, 121083 ○
- 74 A single dose of heated chemo-immunotherapy for long-term tumor inhibition. **2022**, 47, 101650 ○
- 73 Immunotherapy in gynecologic malignancies. **2023**, 506-520.e7 ○
- 72 Drug Resistance in Lung Cancer. **2022**, ○
- 71 Protein kinase C β mediates immunosuppression in lung adenocarcinoma. **2022**, 14, ○
- 70 Distinct Dynamics of Migratory Response to PD-1 and CTLA-4 Blockade Reveals New Mechanistic Insights for Potential T-Cell Reinvigoration following Immune Checkpoint Blockade. **2022**, 11, 3534 ○
- 69 Clonal evolution and expansion associated with therapy resistance and relapse of Colorectal Cancer. **2022**, 108445 ○
- 68 A Phase 1 First-in-Human Study of FS118, a Tetravalent Bispecific Antibody Targeting LAG-3 and PD-L1 in Patients with Advanced Cancer and PD-L1 Resistance. OF1-OF11 ○
- 67 Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1/PD-L1 blockade. **2023**, 66, 100907 ○
- 66 Interdisciplinary Approach in Neurological Cancers. **2022**, ○
- 65 Non-genetic adaptive resistance to KRASG12C inhibition: EMT is not the only culprit. 12, ○
- 64 Galectin-9/Tim-3 pathway mediates dopaminergic neurodegeneration in MPTP-induced mouse model of Parkinson's disease. 15, ○
- 63 Plasma galectins and metabolites in advanced head and neck carcinomas: evidence of distinct immune characteristics linked to hypopharyngeal tumors. **2023**, 12, 1

62	Programmed Cell Death-Ligand 1 in Head and Neck Squamous Cell Carcinoma: Molecular Insights, Preclinical and Clinical Data, and Therapies. 2022 , 23, 15384	3
61	CHI3L1 enhances melanoma lung metastasis via regulation of T cell co-stimulators and CTLA-4/B7 axis. 13,	0
60	Molecular targeted therapy: A new avenue in glioblastoma treatment (Review). 2022 , 25,	0
59	Mechanisms and Strategies to Overcome PD-1/PD-L1 Blockade Resistance in Triple-Negative Breast Cancer. 2023 , 15, 104	0
58	Immune Checkpoints and targeted agents in relapse and graft-versus-host disease after hematopoietic stem cell transplantation.	0
57	Tumor-Infiltrating Lymphocytes and Immune Response in HER2-Positive Breast Cancer. 2022 , 14, 6034	1
56	Resistance to immune checkpoint inhibitors and the tumor microenvironment.	0
55	Immune dysfunctions affecting bone marrow V β V α T cells in multiple myeloma: Role of immune checkpoints and disease status. 13,	0
54	Genomic Immune Evasion: Diagnostic and Therapeutic Opportunities in Head and Neck Squamous Cell Carcinomas. 2022 , 11, 7259	0
53	Transforming growth factor- β signalling in tumour resistance to the anti-PD -(L)1 therapy: Updated.	1
52	Potent molecular-targeted therapies for advanced esophageal squamous cell carcinoma. 2023 , 15, 175883592211383	1
51	Combined Immune Checkpoint Blockade Enhances Antiviral Immunity against Bovine Leukemia Virus.	0
50	Immune Checkpoint Therapy: A New Opportunity for Cancer Treatment. 2023 , 1-20	0
49	Mechanisms of Resistance to Immunotherapies in Cancer. 2023 , 1-30	0
48	Configuring Therapeutic Aspects of Immune Checkpoints in Lung Cancer. 2023 , 15, 543	0
47	The promise of targeting heme and mitochondrial respiration in normalizing tumor microenvironment and potentiating immunotherapy. 12,	0
46	Impact of mouse model tumor implantation site on acquired resistance to anti-PD-1 immune checkpoint therapy. 13,	0
45	TIM-3 Is a Potential Immune Checkpoint Target in Cats with Mammary Carcinoma. 2023 , 15, 384	0

44	Clinical Significance of Signal Regulatory Protein Alpha (SIRP α) Expression in Hepatocellular Carcinoma.	o
43	Case Report: Chemotherapy-free treatment with camrelizumab and anlotinib for elderly patients with KRAS and TP53 mutated advanced lung cancer. 14,	o
42	Guadecitabine increases response to combined anti-CTLA-4 and anti-PD-1 treatment in mouse melanoma in vivo by controlling the responses of T-cells, myeloid derived suppressor cells and NK cells.	o
41	Emerging Biomarkers in Immune Oncology to Guide Lung Cancer Management.	o
40	Tumor Microenvironment before and after Chemoradiation in Locally Advanced Rectal Cancer: Beyond PD-L1. 2023 , 15, 276	o
39	The Tumor Immune Microenvironment in Primary CNS Neoplasms: A Review of Current Knowledge and Therapeutic Approaches. 2023 , 24, 2020	o
38	HNRNPC suppresses tumor immune microenvironment by activating Treg cells promoting the progression of prostate cancer.	o
37	Stimulation of natural killer cells with small molecule inhibitors of CD38 for the treatment of neuroblastoma.	o
36	STK11 loss and SMARCB1 deficiency mutation in a dedifferentiated lung cancer patient present response to neo-adjuvant treatment with pembrolizumab and platinum doublet: A case report. 13,	o
35	Mechanisms of drug resistance to immune checkpoint inhibitors in non-small cell lung cancer. 14,	1
34	The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma. 2023 , 14,	o
33	Immunotherapy of thymic epithelial tumors: molecular understandings and clinical perspectives. 2023 , 22,	o
32	ICI-based therapies: A new strategy for oral potentially malignant disorders. 2023 , 140, 106388	o
31	APRRX1 Signature Identifies TIM-3 and VISTA as Potential Immune Checkpoint Targets in a Subgroup of Microsatellite Stable Colorectal Cancer Liver Metastases. 2023 , 3, 235-244	o
30	Tumor microenvironment-mediated immune evasion in hepatocellular carcinoma. 14,	o
29	Immunotherapy in Melanoma: Recent Advances and Future Directions. 2023 , 15, 1106	o
28	Advances in the Study of Hyperprogression of Different Tumors Treated with PD-1/PD-L1 Antibody and the Mechanisms of Its Occurrence. 2023 , 15, 1314	o
27	The role of LncRNAs in tumor immunotherapy. 2023 , 23,	o

26	Gamma delta T-cell-based immune checkpoint therapy: attractive candidate for antitumor treatment. 2023 , 22,	1
25	Cross-talk between cancer stem cells and immune cells: potential therapeutic targets in the tumor immune microenvironment. 2023 , 22,	0
24	Emerging therapeutic strategies for enhancing sensitivity and countering resistance to programmed cell death protein 1 or programmed death-ligand 1 inhibitors in non-small cell lung cancer. 2023 , 129, 1319-1350	0
23	⁸⁹ Zr-immuno-PET using the anti-LAG-3 tracer [⁸⁹ Zr]Zr-BI 754111: demonstrating target specific binding in NSCLC and HNSCC.	0
22	Resistance mechanisms of immune checkpoint inhibition in lymphoma: Focusing on the tumor microenvironment. 14,	0
21	The Role of Different Immunocompetent Cell Populations in the Pathogenesis of Head and Neck Cancer Regulatory Mechanisms of Pro- and Anti-Cancer Activity and Their Impact on Immunotherapy. 2023 , 15, 1642	0
20	Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy. 2023 , 11, e005920	0
19	Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors. 2023 , 11, e005921	0
18	Acute rejection was observed in a combination therapy of CTLA-4 and PD-1 inhibitors before liver transplantation: A case report and literature review. 2023 ,	0
17	Inappropriate Expression of PD-1 and CTLA-4 Checkpoints in Myeloma Patients Is More Pronounced at Diagnosis: Implications for Time to Progression and Response to Therapeutic Checkpoint Inhibitors. 2023 , 24, 5730	0
16	Guadecitabine increases response to combined anti-CTLA-4 and anti-PD-1 treatment in mouse melanoma in vivo by controlling T-cells, myeloid derived suppressor and NK cells. 2023 , 42,	0
15	Immunotherapy for hepatocellular carcinoma: Recent advances and future targets. 2023 , 244, 108387	0
14	FoxP3 Expression in Tumor-Infiltrating Lymphocytes as Potential Predictor of Response to Immune Checkpoint Inhibitors in Patients with Advanced Melanoma and Non-Small Cell Lung Cancer. 2023 , 15, 1901	0
13	Immunotherapy for Primary Cancers of Central Nervous System. 2023 , 1-21	0
12	Galectin-9 in Gastroenterological Cancer. 2023 , 24, 6174	0
11	Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Strategies and Biomarkers Predicting Response and/or Resistance. 2023 , 11, 1020	0
10	Peripheral PD-1 and Tim-3 percentages are associated with primary sites and pathological types of peritoneal neoplasms. 2023 , 23,	0
9	The landscape of objective response rate of anti-PD-1/L1 monotherapy across 31 types of cancer: a system review and novel biomarker investigating.	0

- 8 Mechanisms of resistance to melanoma immunotherapy. **2023**, 17, 51-56
- 7 Dynamic gut microbiota changes in patients with advanced malignancies experiencing secondary resistance to immune checkpoint inhibitors and immune-related adverse events. 13, **2023**, 21,
- 6 Recent advances and future challenges of tumor vaccination therapy for recurrent glioblastoma. **2023**, 21,
- 5 Recent advancements in the B7/CD28 immune checkpoint families: new biology and clinical therapeutic strategies.
- 4 Immune-checkpoint inhibitor resistance in cancer treatment: Current progress and future directions. **2023**, 562, 216182
- 3 Hepatocellular carcinoma (HCC) immunotherapy by anti-PD-1 monoclonal antibodies; a rapidly evolving strategy. **2023**, 154473
- 2 Exploration of the immunogenetic landscape of hyperprogressive disease after combined immunotherapy in cancer patients. **2023**, 106720
- 1 The progress on the relationship between gut microbiota and immune checkpoint blockade in tumors. 1-20